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Introduction
The Polish Society of Hypertension (PTNT) presents a new edition of its guidelines for 
the management of hypertension.
During four years that have passed since publication of the previous 2011 guidelines, 
results of multiple studies and metaanalyses evaluating antihypertensive therapy have been 
published. These results have extended the range of available information, leading to modi-
fication of some previous concepts, such as the approach to the treatment of resistant and 
secondary hypertension, including interventional treatment.
The present document is generally based on the 2011 PTNT guidelines and includes 
some of the changes, which were considered appropriate by the authors of the present 
guidelines, that were introduced in the most recent European Society of Hypertension/ 
/European Society of Cardiology (ESH/ESC) guidelines published in 2013. 
A novel aspect of the 2015 PTNT guidelines has been the addition of an extensive chap-
ter on the management of hypertension in children, based on the fact that hypertension 
specialists in training may stem from both internists and paediatricians, with an attempt to 
make this guideline edition more practical, taking into consideration some specific Polish 
conditions and issues regarding the diagnosis and drug treatment.
A traffic light signalling system-based classification has been introduced in the tables 
summarizing the basic principles of the management of hypertension in special patient 
populations, with the three lights corresponding in a simplified way to typical recommenda-
tion classes along with their levels of evidence, but also reflecting expert opinion to a greater 
degree compared to the 2013 ESH/ESC guidelines.
These colours mean:
green — a given management approach is recommended, generally based on clear 
evidence from research studies, or unequivocal expert opinion resulting from eve-
ryday clinical practice;
yellow — a given management approach is suggested as appropriate despite lacking 
or equivocal evidence from research studies, based on the opinion of the majority of 
experts reflecting common sense and their personal clinical experience;
red — a given management approach is considered harmful, generally based on 
clear evidence from research studies, or not justified due to lack of supporting 
evidence.
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1. Epidemiology and prevention  
of hypertension
Hypertension remains the most important risk 
factor for premature mortality worldwide. Blood 
pressure (BP) values show a linear correlation with 
mortality and the incidence of cardiovascular disease 
(myocardial infarction, stroke, heart failure, periphe-
ral vascular disease) and chronic kidney disease in 
all age and ethnic groups in both women and men. 
Among subjects above 50 years of age, systolic blood 
pressure (SBP) better describes cardiovascular risk, 
and an additional marker of increased risk is pulse 
pressure or the difference between SBP and diastolic 
blood pressure (DBP).
Data obtained during the last 20 years indicate 
an increasing prevalence of hypertension in Poland. 
The NATPOL 2011 study showed that over 10 years, 
the prevalence of hypertension in individuals aged 
18–79 years increased from 30% to 32%, or approxi-
mately 9 million. In addition, the POLSENIOR 
study indicates that hypertension is present in about 
one million of people above 80 years of age. If these 
trends continue, it has been estimated that the num-
ber of subjects with hypertension will have increased 
by half until 2035.
Development of hypertension may be best pre-
vented by interventions targeted at environmental 
factors. The most effective approach to prevent or 
delay development of hypertension (primary pre-
vention) is lifestyle modification, in particular pre-
vention of obesity and increasing physical activity. 
Primary prevention may be divided into population 
efforts, directed at the general population, and pre-
vention targeted at those at an increased risk of hy-
pertension. The latter should focus on the following 
groups:
1. Subjects with a family history of premature car-
diovascular disease (stroke, myocardial infarction, 
heart failure) — below 65 years of age in women 
and 55 years of age in men.
2. Patients with diabetes or concomitant kidney di-
sease.
3. Subjects with two or more conventional cardio-
vascular risk factors.
4. Subjects with high normal BP (≥ 130/85 mm Hg).
5. Subjects with white coat hypertension.
Preventive efforts should also be targeted at tho-
se with established hypertension (secondary pre-
vention). The goal of early secondary prevention is 
to increase identification of the disease in its early 
asymptomatic period, when target organ damage is 
absent or limited. About 30% of subjects are una-
ware of hypertension which results from the fact 
that nearly 40% of people in Poland do not know 
their BP values. Due to this low identification of 
hypertension in Poland, screening BP measurements 
are recommended in all adults at least once a year 
regardless of previous BP values.
Late secondary prevention or tertiary preven-
tion includes therapeutic interventions in subjects 
with established disease to prevent or at least delay 
adverse sequelae of hypertension (cardiovascular and 
renal complications). Public awareness of the risks 
associated with high BP has increased but remains 
unsatisfactory. The NATPOL 2011 study showed 
that the proportion of subjects with the diagnosis 
of hypertension who remained untreated decreased 
from 18% to 13%.
A positive trend has been the observed increase in 
the proportion of hypertensive subjects with adequ-
ately controlled BP from 12% to 26%. This is rela-
ted to the fact that the proportion of adequate BP 
control among treated subjects increased from 22% 
to 42%.
2. Diagnosis and classification
The diagnosis of hypertension is based on properly 
performed office BP measurements. Due to the ban 
on the use of mercury in the European Union, se-
miautomatic auscultatory or oscillometric sphygmo-
manometers are currently recommended for BP me-
asurements. Obtaining reliable BP value requires use 
of an adequately accurate device, appropriate patient 
preparation, and proper measurement technique (Ta-
ble I). Brachial BP measurements are recommended, 
and the list of certified BP measurement devices may 
be found at the Polish Society of Hypertension (Pol-
skie Towarzystwo Nadciśnienia Tętniczego, PTNT) 
website (www.nadcisnienietetnicze.pl/dla_lekarzy/
zalecenia_i_standardy/zalecenia_ptnt).
Hypertension may be diagnosed if average BP va-
lues (calculated based on at least two measurements 
on at least two different visits) are equal to or higher 
than 140 mm Hg (SBP) and/or 90 mm Hg (DBP).
In patients with BP values below 160/100 mm Hg, 
the diagnosis of hypertension should be confirmed by 
ambulatory blood pressure monitoring (ABPM) or, 
if this method is not available, by home BP measure-
ments (using the approach shown in Table II), using 
different threshold values as shown in Table III.
In patients with BP values ≥ 180/≥ 110 mm Hg, 
the diagnosis of hypertension may be made at the 
first visit after excluding the effect of factors leading 
to acute BP elevation, e.g. anxiety, pain, or alcohol 
intake.
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The diagnosis of hypertension may also be made 
based on reliable data from the history or patient 
medical records (BP values or the use of antihyper-
tensive medications).
In the present 2015 PTNT guidelines, we re-
tained the previous classification of hypertension 
based on office BP measurements, with three 
grades of severity and the separate subtype of 
isolated systolic hypertension (ISH). The classi-
fication also continues to categorize BP values in 
the normal range into optimal, normal, and high 
normal BP.
Table I. General principles and proper technique of office blood pressure measurements
Equipment requirements
Validated device with an arm cuff (see www.nadcisnienietetnicze.pl/dla_lekarzy/zalecenia_i_standardy/zalecenia_ptnt)
Cuff size adjusted to the patient arm size (ideally, the length of the bladder should be equal to 80% of the arm circumference, and its width to 40% of 
the arm circumference)
Patient preparation
Patients should refrain from drinking coffee and smoking cigarettes for at least 30 minutes before the measurement
Immediately before the measurement, patients should rest for several minutes in a quiet room in a sitting position with their back supported
During the measurement, the patient should be sitting with his/her back supported, upper arm bare and free from any restrictive clothing, loosely 
supported with the elbow at the level of 4th intercostal space
The cuff should be placed at the level of the heart regardless of the patient position
Measurement technique
The cuff should be inflated to 30 mm Hg above the audible sounds (palpable pulse)
The cuff should be deflated at a rate of 2 mm Hg/s
Initially, BP should be measured on both arms, with further measurements on the arm with the higher BP reading
Systolic blood pressure (SBP) is defined as the appearance of the first tone during cuff deflation — Korotkoff phase I
Diastolic blood pressure (DBP) is defined as the disappearance of the last tone during cuff deflation — Korotkoff phase V
BP should be calculated as the mean of 2 measurements performed 1–2 minutes apart during the same visit
Pulse rate should be measured following the second BP measurement
Special situations
Third BP measurement should be performed (and taken into account when calculating the mean BP value) if the difference between the first and the 
second measurement is larger than 10 mm Hg
If a BP difference was found between the arms, the higher value should be taken as actual BP
In the elderly, diabetic patients, and patients with other conditions that might result in orthostatic hypotension, BP should also be measured at  
1 and 3 minutes after standing
BP — blood pressure
Table II. Recommendations regarding home blood pressure measurements
Fully automated devices with an arm cuff are recommended (see www.nadcisnienietetnicze.pl/dla_lekarzy/zalecenia_i_standardy/zalecenia_ptnt).
Measurements should be performed during 7 subsequent days
Two BP measurements should be performed several minutes apart in the morning and in the evening, at constant times of the day, possibly at equal 
intervals (e.g., 6.00 AM–6.00 PM, 7.00 AM–7.00 PM). Measurements should be performed immediately before drug intake, and in the morning also 
before the meal
Measurements should be performed according to the principles described in Table 1
The patient should record BP values measured on subsequent days in a diary. Devices with a memory function or connected to a printer may also 
be used
For calculation of the mean BP for HBPM, values obtained during the first day should be discarded
Purposefulness of HBPM should be carefully considered in patients with an elevated level of anxiety
Purposefulness of HBPM should be carefully considered in patients who are inclined to introduce frequent treatment self-modifications
Home BP values should not be used for self-modifications of the therapy by the patient
BP — blood pressure; HBPM — home blood pressure monitoring
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Table III. Diagnosis of hypertension based on office and out-of-office blood pressure measurements
Category Systolic BP [mm Hg] Diastolic BP [mm Hg]
Office BP measurements ≥ 140 and/or ≥ 90
Ambulatory BP measurements
— daytime (or awake) ≥ 135 and/or ≥ 85
— nighttime (or sleep) ≥ 120 and/or ≥ 70
— mean 24-hour ≥ 130 and/or ≥ 80
Home BP measurements ≥ 135 and/or ≥ 85
BP — blood pressure
Table IV. Definitions and classification of office blood pressure levels
Category Systolic BP [mm Hg] Diastolic BP [mm Hg]
Optimal BP < 120 and < 80
Normal BP 120–129 and/or 80–84
High normal BP 130–139 and/or 85–89
Grade 1 hypertension 140–149 and/or 90–99
Grade 2 hypertension 160–179 and/or 100–109
Grade 3 hypertension ≥ 180 and/or ≥ 110
Isolated systolic hypertension ≥ 140 and < 90
BP — blood pressure
Detailed classification of hypertension is shown 
in Table IV.
Blood pressure values are of major importance 
when stratifying patient risk. The remaining compo-
nents required for this assessment must be obtained 
by the physician based on history, physical examina-
tion, and laboratory tests.
3. Investigations
At the time of the diagnosis of hypertension, all pa-
tients should undergo comprehensive evaluation that inc-
ludes detailed history, physical examination, and selected 
laboratory tests and other investigations as required.
The goals of clinical evaluation include identifi-
cation of:
1. Other concomitant cardiovascular risk factors.
2. Target organ damage and the presence and se-
verity of other diseases, including cardiovascular 
disease, kidney disease, and diabetes.
3. The cause of elevated BP and indications for inve-
stigating for possible secondary hypertension.
3.1. Patient history
Important issues to consider during history taking 
should include duration of hypertension, previously 
observed BP values, and previous treatment and its 
effects. Data should be obtained regarding possible se-
condary nature of hypertension, the presence of risk 
factors and concomitant diseases, and the family histo-
ry of hypertension, cardiovascular disease, and kidney 
disease that might indicate a hereditary background. 
Other medications taken by the patient that might 
affect BP values should be noted, along with possible 
evidence of noncompliance (the patient does not know 
names and doses of the medications, irregular visits, 
missing medical records). In women, BP values during 
pregnancy should be ascertained. History should also be 
taken regarding substance use, including alcohol intake 
and tobacco smoking (quantified by the number of 
pack-years), changes in body weight, and dietary habits.
3.2. Physical examination
Complete physical examination should be perfor-
med in all patients, taking particular note of findings 
indicating secondary hypertension and the presence 
of target organ damage.
Patient body weight and height should be docu-
mented, along with calculation of the body mass index 
(BMI), defined as body weight in kilograms divided 
by squared height in metres. Overweight is defined as 
BMI ≥ 25 kg/m2, and obesity as BMI ≥ 30 kg/m2.
Waist circumference should also be evaluated by 
measuring abdominal circumference in a horizontal 
plane at the superior aspect of the iliac crests to iden-
tify abdominal obesity. As per the 2013 European 
Society of Hypertension (ESH)/European Society 
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of Cardiology (ESC) guidelines, abdominal obesity 
is defined as an increased waist circumference of 
≥ 102 cm in men and ≥ 88 cm in women.
3.3. Laboratory investigations
Laboratory investigations include routine tests 
necessary in all patients with hypertension, additio-
nal tests performed in selected patients, and specia-
list tests performed during more extensive diagnostic 
work-up in reference centres.
Routine tests include:
•	 full blood count;
•	 fasting blood glucose level;
•	 sodium and potassium level;
•	 total cholesterol, high-density lipoprotein (HDL) 
cholesterol, low-density lipoprotein (LDL) cho-
lesterol, and triglyceride level;
•	 serum creatinine level with estimation of the glo-
merular filtration rate (eGFR) using the Modifica-
tion of Diet in Renal Disease (MDRD) formula:
eGFR [mL/min/1.73 m2] = 186.3 × serum 
creatinine–1.154 [mg/dL] × age–0.203 × C
 where C is a coefficient equal to 1 in men and   
 0.742 in women;
•	 serum uric acid level;
•	 urine examination with evaluation of albuminuria;
•	 electrocardiogram (ECG).
Additional tests are performed in those patients 
in whom history, physical examination or results of 
basic tests indicate a need for extended diagnostic 
work-up. These tests are characterized by an incre-
ased sensitivity of identifying subclinical target organ 
damage and allow more precise evaluation of the 
cardiovascular risk. Additional tests include echo-
cardiography, carotid and renal artery ultrasound, 
evaluation of albuminuria with its quantification if 
qualitative evaluation yields a positive result, 24-hour 
urinary sodium and potassium excretion, fundosco-
py, oral glucose tolerance test (OGTT), 24-hour 
ABPM, 24-hour ECG monitoring if arrhythmia is 
present, and measurements of the ankle-brachial in-
dex (ABI) and the pulse wave velocity (PWV).
Specialized tests are used to identify some forms 
of target organ damage (e.g., magnetic resonance 
imaging in subjects with suspected hypertensive en-
cephalopathy) and are usually necessary to confirm 
or exclude secondary hypertension.
A summary of all investigations performed in pa-
tients with hypertension is shown in Table V.




Serum total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides
Serum potassium, sodium, and uric acid





Carotid and renal artery ultrasound
Quantitative evaluation of proteinuria (if positive reagent strip test); urinary sodium and potassium
Fundoscopy
Oral glucose tolerance test
24-hour ambulatory blood pressure monitoring
24-hour Holter monitoring if arrhythmias
Ankle-brachial index measurement
Pulse wave velocity measurement
Specialist tests
Further search for cerebral, cardiac, renal and vascular damage, mandatory in resistant or complicated hypertension
Search for secondary hypertension when suggested by clinical evidence or results of previous investigations
ECG — electrocardiogram; GFR — glomerular filtration rate; HDL — high-density lipoprotein; LDL — low-density lipoprotein
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3.4. Ambulatory blood pressure monitoring
Increasing the number of BP measurements per-
formed out-of-office, in conditions that reflect the 
usual patient environment, allows more reliable 
evaluation of actual BP values. Different diagnostic 
thresholds for out-of-office measurements compared 
to office measurements have been included in the 
diagnostic criteria for hypertension (Table III). Nor-
mal BP by ABPM is defined as mean daytime values 
below 135/85 mm Hg, mean nighttime values below 
120/70 mm Hg, and mean 24-hour values below 
130/80 mm Hg. Mean BP values obtained by ABPM 
or home blood pressure monitoring (HBPM) better 
reflect the risk of cardiovascular events and correlate 
more strongly with the presence of subclinical target 
organ damage compared to office BP values. Out-of
-office measurements allow the diagnosis of masked 
hypertension, which is characterized by elevated BP 
values only in ABPM or HBPM, and are necessary 
for modifications of the timing of antihypertensi-
ve drug administration. Despite clear clinical utility, 
ABPM also has some limitations including high cost, 
still suboptimal availability, and unclear reproducibili-
ty of findings (though the latter is higher compared to 
office BP measurements). To obtain reliable measure-
ments, validated devices should be used, and care sho-
uld be taken to ensure proper measurement technique.
The use of ABPM has increased in the recent 
years, as reflected by extended indications for this 
investigation in the 2011 British Society of Hyper-
tension (BSH)/National Institute for Clinical Excel-
lence (NICE) guidelines and the 2013 ESH/ESC 
guidelines. ABPM allow detection of prognostically 
adverse phenomena including excessive morning BP 
surge, and non-dipper and extreme-dipper patterns 
of the circadian BP rhythm. Clearly, ABPM should 
be widely used to diagnose hypertension, particularly 
in patients with grade 1 hypertension by office BP 
measurements. Specific indications for ABPM are 
listed in Table VI.
Table VI. Indications for and technique of ambulatory blood pressure measurements
Indications for ABPM
Confirmation of the diagnosis of hypertension in patients with grade 1 hypertension by office BP measurements and low/moderate cardiovascular 
risk
Suspicion of white-coat hypertension
— grade 1 hypertension by office BP measurements
— long-standing hypertension without target organ damage and/or with low global cardiovascular risk
— large BP differences in office measurements (> 20 mm Hg) or differences between home and office readings
Suspicion of masked hypertension
— high normal BP by office measurements
— normal office BP readings in individuals with subclinical target organ damage or high global cardiovascular risk
— suspicion of nocturnal hypertension and/or abnormal 24-hour BP pattern
Suspicion of hypotension (dizziness, falls, presyncope, syncope) or autonomic system dysfunction
Identification of true resistant or pseudo resistant hypertension
— suspicion of white-coat effect in treated hypertensives
Hypertension in pregnant women
Hypertension in patients with glaucoma
Technique of ABPM
First, measure BP on both arms with a conventional sphygmomanometer according to the general principles (see Table 1)
Depending on BP difference between arms:
≤ 10 mm Hg (SBP) — place the cuff on the non-dominant arm
> 10 mm Hg — place the cuff on the arm with higher BP reading
Choose an appropriately-sized cuff and measure BP using the automated device
If the difference between initial BP reading and BP read by the automated device is greater than 5 mm Hg, re-adjust the cuff
Set BP measurement intervals (preferred intervals 15–20 minutes during the day and 30 minutes during the night, maximum acceptable intervals 
30 minutes during the day and 60 minutes during the night)
Switch off BP reading display
Provide the patient with a diary to record activity during the monitoring (along with a contact phone number)
A recording is acceptable if it includes at least 70% of the planned BP readings during the day and night
ABPM — ambulatory blood pressure monitoring; BP — blood pressure; SBP — systolic blood pressure
arterial hypertension 2015, vol. 19, no. 2
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3.5. Home blood pressure measurements
Home BP measurements not only reduce the risk 
of a white-coat effect, often observed during office 
BP measurements, but also show good agreement 
with daytime ABPM measurements. In addition, 
home BP values correlate with cardiovascular risk 
better than office values. Abnormal home BP values 
are defined as the average of several measurements 
greater than or equal to 135 and/or 85 mm Hg.
During long-term management, 1–2 measure-
ments per week are recommended, with values re-
corded in a patient diary. Daily home measurements 
should be advised during the week prior to a fol-
low-up visit (2 measurements in the morning and 
2 measurements in the evening, before medication 
intake) and are a basis for medication adjustments 
by a physician.
Self-measurement of BP is relatively easy for the 
patient and may contribute to improved compliance 
and treatment effectiveness by engaging the patient 
in the therapeutic process. Prerequisites include te-
aching the patient proper measurement technique 
(Table I) and use of a validated device with an arm 
cuff. Difficulties may arise from the fact that only 
some devices available on the Polish market fulfil the 
quality criteria.
3.6. Assessment of the global cardiovascular risk
In most patients, other concomitant factors affec-
ting the global cardiovascular risk may be detected 
at the time of the diagnosis of hypertension. Thus, 
the management of a hypertensive patient should 
include estimation of cardiovascular risk based on 
the severity of hypertension and the presence of other 
major risk factors, subclinical target organ damage, 
and concomitant diabetes, cardiovascular disease, or 
chronic kidney disease. The risk is then categorized 
as low, moderate, high, or very high. Assessment 
of the global cardiovascular risk is the basis of 
therapeutic choices regarding many aspects of the 
management and treatment strategy in a hyper-
tensive patient.
Table VII summarizes risk factors, subclinical tar-
get organ damage, and cardiovascular and kidney di-
sease taken into account when evaluating the risk of 
a cardiovascular event, and stratification of the global 
risk based on these factors is shown in Figure 1.
When based on the Framingham model, inter-
pretation of the level of risk (low, moderate, high, 
or very high), which is higher compared to heal-
thy subjects without risk factors, indicates that the 
10-year absolute risk of cardiovascular disease is below 
15%, 15–20%, 20–30%, and above 30%, respecti-
vely. Using the European Systematic Coronary Risk 
Evaluation (SCORE) model, the 10-year absolute 
risk of cardiovascular death for the above risk catego-
ries is below 4%, 4%, 5–8%, and above 8%, respec-
tively. Use of the SCORE risk chart is recommended 
in subjects above 40 years of age free from cardio-
vascular disease and diabetes. For younger subjects, 
a relative risk chart is available (see: Eur. Heart J. 2012; 
33: 1635–1701).
In patients with an abnormal circadian BP pattern 
(non-dippers, extreme dippers), the global risk is in-
creased in relation to the observed BP values.
In patients with masked hypertension, the global 
risk is similar to that in subjects with office hyper-
tension. In contrast, the risk in those with white-coat 
hypertension is lower than indicated by office BP 
measurements.
Clinical profile
Blood pressure [mm Hg]
High normal  
(130–139/85–89)
Grade 1 hypertension 
(140–159/90–99)
Grade 2 hypertension 
(160–179/100–109)
Grade 3 hypertension 
(≥ 180/110)
No risk factors Average* Low Moderate High
1–2 risk factors Low Moderate Moderate High
≥ 3 risk factors Moderate Moderate High High
Target organ damage, diabetes,  
CKD stage 3 High High High Very high
Overt cardiovascular disease,  
CKD stage ≥ 4 Very high Very high Very high Very high
Figure 1. Evaluation of the global cardiovascular risk in hypertensive patients  
CKD — chronic kidney disease (stage 3: eGFR 30–59 mL/min/1.73 m2; stage ≥ 4: eGFR < 30 mL/min/1.73 m2) 
*Denotes cardiovascular risk in the healthy population, which is lower than a “low” global cardiovascular risk in respective age groups
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Table VII. Risk factors, target organ damage, and metabolic, cardiovascular, and renal disease used for stratification of the 
global cardiovascular risk (see Figure 1)
Risk factors
Male sex
Age (men ≥ 55 years, women ≥ 65 years)
Smoking
Dyslipidaemia
— total cholesterol > 4.9 mmol/L (190 mg/dL), or
— LDL cholesterol > 3.0 mmol/L (115 mg/dL), or
— HDL cholesterol < 1.0 mmol/L (40 mg/dL) in men, < 1.2 mmol/L (46 mg/dL) in women, and/or
— triglycerides > 1.7 mmol/L (150 mg/dL)
Fasting plasma glucose 5.6–6.9 mmol/L (102–125 mg/dL)
Abnormal glucose tolerance test
Obesity (BMI ≥ 30 kg/m2)
Abdominal obesity (waist circumference: men ≥ 102 cm, women ≥ 88 cm — in Caucasians)
Family history of premature CVD (men < 55 years, women > 65 years)
Subclinical target organ damage
Pulse pressure (in the elderly) ≥ 60 mm Hg
Electrocardiographic LVH
— Sokolov-Lyon index > 3.5 mV
— R in aVL > 1.1 mV
— Cornell voltage duration product > 244 mV × ms
or echocardiographic LVH
— LVM index > 115 g/m2 BSA in men, > 95 g/m2 BSA in women
Carotid artery wall thickening (IMT > 0.9 mm) or the presence of a atherosclerotic plaque
Carotid artery-femoral artery PWV > 10 m/s
Ankle-brachial index < 0.9
Chronic kidney disease with eGFR 30–60 mL/min/1.73 m2 BSA
Albuminuria 30–300 mg/24 h or urinary albumin-creatinine ratio 30–300 mg/g (3.4–34 mg/mmol) (preferentially on morning spot urine)
Diabetes
Fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL) on two measurements
Random glucose ≥ 11.1 mmol/L (200 mg/dL) if symptoms of hyperglycaemia are present, such as polydipsia, polyuria, fatigue
Post-load plasma glucose ≥ 11.1 mmol/L (200 mg/dL)
Overt cardiovascular or renal disease
Cerebrovascular disease: ischemic stroke, cerebral haemorrhage, TIA
Cardiovascular disease: myocardial infarction, angina, myocardial revascularization with PCI or CABG
Heart failure, including heart failure with preserved EF
Symptomatic lower extremities peripheral arterial disease
Chronic kidney disease with eGFR < 30 mL/min/1.73 m2 BSA, proteinuria > 300 mg/24 h
Advanced retinopathy: haemorrhages or exudates, papilledema
BMI — body mass index; BSA — body surface area; CABG — coronary artery bypass grafting; CKD — chronic kidney disease; CVD — cardiovascular disease; EF — ejection fraction;  
eGFR — estimated glomerular filtration rate; HDL — high-density lipoprotein; IMT — intima-media thickness; LDL — low-density lipoprotein LVH — left ventricular hypertrophy; LVM — left ven-
tricular mass; PCI — percutaneous coronary intervention; PWV — pulse wave velocity; TIA — transient ischemic attack
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4. Therapeutic management
4.1. Overall goals and principles of the 
management
The basic goal of treatment in patients with 
hypertension is to reduce mortality and the global 
risk of cardiovascular and renal complications. In 
particular, drug treatment should reduce BP valu-
es to target levels established for hypertensives or, 
if it is not feasible, as close to these values as possible. 
This is based on numerous observations that effec-
tive BP lowering reduces the risk of cardiovascular 
events, particularly stroke and acute coronary events, 
and delays progression of renal disease. At the same 
time, global treatment strategy in the hypertensive 
patient should include correcting all other modi-
fiable cardiovascular risk factors.
4.1.1. Initiation of antihypertensive therapy
The decision to initiate antihypertensive therapy 
should be preceded by history taking and physical 
examination, including BP measurements according 
to the above defined standards. If grade 3 (BP ≥ 180 
and/or 110 mm Hg) or grade 2 (BP ≥ 160 and/or 
100 mm Hg) hypertension is found, as confirmed by 
at least two measurements at one or two occasions, 
respectively, drug treatment should be initiated im-
mediately along with necessary non-pharmacological 
measures, prior to complete evaluation of the risk 
profile.
If the observed BP values indicate grade 1 hy-
pertension (140–159/90–99 mm Hg), non-phar-
macological measures should be instituted, and the 
decision to initiate drug therapy should be made 
after comprehensive risk stratification and evaluation 
of the effects of non-drug treatment, and if the global 
cardiovascular risk is low or moderate, also following 
additional verification of the diagnosis of hyperten-
sion by ABPM. This indicates that it is not necessary 
to start drug treatment in patients with white-coat 
hypertension, and only lifestyle changes and perio-
dic reevaluation by ABPM should be recommended 
instead, as these individuals are at an increased risk of 
developing true hypertension. Despite little evidence 
of benefits of antihypertensive therapy in patients 
with grade 1 hypertension, there are arguments in 
favor of initiating drug treatment at some point also 
in these patients, as summarized in the 2013 ESH/ 
/ESC guidelines: 1. withholding drug therapy leads 
over time to an increase in the global risk which is 
difficult to reverse; 2. appropriately individualized 
antihypertensive drug therapy is effective and well 
tolerated long-term; and 3. cheap antihypertensive 
drugs are available that provide a good benefit-to-
cost ratio.
If grade 1 hypertension is confirmed in an elderly 
patient, the decision to initiate drug treatment sho-
uld be more cautious and is not obligatory due to 
the fact that evidence of benefits of antihypertensive 
drug therapy in this age group come from studies 
that recruited patients with at least grade 2 hyperten-
sion. On the other hand, elderly patients constituted 
a significant proportion of patient populations in 
many large-scale clinical trials that showed benefits 
of antihypertensive drug therapy.
The 2013 ESH/ESC guidelines suggested that li-
festyle changes only should be instituted in young 
subjects with grade 1 ISH, as there is no evidence of 
treatment benefits in this age group, and their cen-
tral aortic pressure is often normal. It seems that the 
decision to initiate drug treatment in these patients 
should be individualized based on the evaluation of 
their global cardiovascular risk, possibly measure-
ment of central BP, and after mandatory verification 
of the diagnosis of hypertension by ABPM.
Routine antihypertensive drug therapy in patients 
with high normal BP (130–139/85–89 mm Hg) 
continues to be considered unnecessary regardless 
of the presence of metabolic syndrome, diabetes, 
and/or cardiovascular disease (ischemic heart dise-
ase, previous myocardial infarction or stroke). In 
the latter group, antihypertensive drug may be ne-
cessary for other indications (secondary prevention 
of myocardial infarction, treatment of heart failure, 
nephroprotection).
Non-drug treatment involving lifestyle changes 
is a necessary component of the management of hy-
pertension and should be initiated at the first visit in 
all patients with suspected hypertension, including 
those with high normal BP. Initiating drug treatment 
does not mean that lifestyle changes are no lon-
ger necessary. At the same time, due to low patient 
compliance regarding lifestyle changes, institution of 
non-drug treatment should not delay the decision 
to initiate antihypertensive drug therapy beyond the 
time limits set for this decision, particularly in pa-
tients with higher cardiovascular risk.
The principles of initiating drug therapy are sum-
marized in Figure 2.
4.1.2. Target blood pressure
Target BP is a threshold value below which pa-
tient’s BP should be kept during optimal antihy-
pertensive therapy. Only once target BP values are 
reached, there is no need for further therapy inten-
sification. In the past, recommendations regarding 
target BP values were often changed with publication 
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Clinical profile
Blood pressure [mm Hg]
High normal  
(130–139/85–89)
Grade 1 hypertension 
(140–159/90–99)
Grade 2 hypertension 
(160–179/100–109)
Grade 3 hypertension 
(≥ 180/110)
Non-drug therapy and antihypertensive drug therapy
No risk factors No BP intervention Lifestyle changes
Confirmation by ABPM if BP 
≥ 140/90 after 3 months, 
then add drugs
Lifestyle changes + drug 
treatment starting from 
the 2nd visit
Lifestyle changes  
+ drug treatment  
starting from the  
1st visit
1–2 risk factors Lifestyle changes
≥ 3 risk factors Lifestyle changes Confirmation by ABPM if BP 
≥ 140/90 after 3 months, 
then add drugs
Lifestyle changes + drug 
treatment starting from 
the 2nd visit
Target organ damage, diabe-
tes, CKD stage 3
Lifestyle changes* Lifestyle changes + drug 
treatment starting from the 
1st visit
Lifestyle changes + drug 
treatment starting from 
the 1st visit
Overt cardiovascular disease, 
CKD stage ≥ 4
Lifestyle changes* Lifestyle changes + drug 
treatment starting from the 
1st visit
Lifestyle changes + drug 
treatment starting from 
the 1st visit
Figure 2. Initiation of antihypertensive therapy in relation to blood pressure values and the global cardiovascular risk
CKD — chronic kidney disease (stage 3: eGFR 30–59 mL/min/1.73 m2; stage ≥ 4: eGFR < 30 mL/min/1.73 m2)
*In the high normal BP range, antihypertensive drugs are often indicated for reasons other than elevated BP (treatment of cardiac events, cardiovascular prevention, nephroprotection)
of the results of large trials comparing benefits of 
different target BP values during treatment. Cur-
rent analyses indicate that optimal reduction of the 
global cardiovascular risk is obtained by reducing 
BP below 140/90 mm Hg in most patients with 
hypertension, including those with concomitant 
ischemic heart disease, previous myocardial in-
farction, or stroke. This major change in the ap-
proach to setting target BP in patients with high ba-
seline cardiovascular risk that occurred in 2009 and 
was maintained in the present guidelines, is related, 
among others, to the existence of a phenomenon of 
the J curve, i.e. relatively higher cardiovascular risk 
with too low on-treatment BP values, which was ob-
served in many large-scale clinical trials. In patients 
at high cardiovascular risk, however, BP should be 
reduced more rapidly to the target values.
There are two exceptions from the target BP given 
above. In patients with diabetes, the recommended 
target BP values are below 140/85 mm Hg. This 
conclusion results from multiple analyses showing 
the nadir of cardiovascular risk at these BP values in 
diabetic patients (based on the ACCORD, HOT, 
and INVEST studies). In patients above 80 years of 
age, more cautious SBP reduction to values below 
150 mm Hg is recommended, based directly on the 
target SBP set in the HYVET trial which was the 
only successful study in this age group.
In patients with ISH, SBP should be reduced be-
low 140 mm Hg but due to low DBP values, advan-
ced age of most patients with this subtype of hyper-
tension, and less aggressive approach to treatment 
in the elderly patients with grade 1 hypertension, 
attempts to reduce SBP to the target values sho-
uld not lead to DBP reduction to very low values 
(< 65 mm Hg).
4.1.3. Follow-up visits
Current practice indicates that in the initial tre-
atment phase, when the diagnosis of hypertension 
is confirmed and treatment is initiated and inten-
sified, follow-up visits should be set at monthly 
intervals, and after adequate BP control is obta-
ined, their frequency may be reduced to once every 
3 months. Intervals between follow-up visits should 
also depend on the degree of patient compliance, 
and the presence of target organ damage, concomi-
tant disease, and other risk factors. The treatment 
plan should be adjusted to patient lifestyle and 
needs, with simplification of the therapy, reduction 
of the daily number of tablets taken by the patient, 
involving family members in the treatment process, 
and tailoring treatment to the financial situation of 
the patient.
4.1.4. Specialist consultation
A specialist consultation should be considered if: 
•	 target BP has not been reached during 6 months 
of therapy despite treatment with 3 drugs in full 
doses, including a diuretic;
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Table VIII. Basic dietary recommendations for hypertensi-
ve patients, aiming for body weight maintenance or reduc-
tion to normal values
Maintain daily caloric intake or reduce it in case of overweight or 
obesity
Increase intake of vegetables and other plant products  
(4–5 servings) rich in potassium, e.g. tomatoes (300 g/day)*
Avoid products with high animal fat content (saturated fatty acids 
and cholesterol)
Substitute fish, fruits, vegetables, and other products containing 
unsaturated fatty acids for fatty animal products
*Excluding patients with renal failure or increased risk of hyperkalaemia
•	 previously well controlled BP worsened despite 
continued use of drugs and without an obvious 
cause indicated by the history;
•	 clinical findings are present that may indicate 
secondary hypertension.
4.1.5. Cessation of antihypertensive drug therapy
Cessation of antihypertensive drug therapy may 
be considered in the following situations:
•	 in low risk patients who are fully compliant with 
non-drug therapy;
•	 in young subjects in whom BP elevation was 
clearly associated with a stressful situation which 
is no longer present;
•	 following a long period (≥ 12 months) of good 
BP control as evidenced by both office and home 
measurements (or ABPM) in patients with grade 
1 hypertension.
In these situations, drug doses should be gradually 
and cautiously reduced or even some drugs comple-
tely withdrawn but one should not withdrew all me-
dications at once, and the patient requires frequent 
BP measurements.
4.2. Non-drug therapy
Non-drug therapy involves lifestyle changes that 
significantly reduce elevated BP, increase effectiveness 
of drug therapy, and probably may reduce the risk of 
cardiovascular events and prevent development of 
hypertension in those with a family history of hyper-
tension. However, due to poor patient compliance 
regarding lifestyle changes, their formal recommen-
dation should never delay initiation of drug therapy 
in high risk patients.
Non-drug therapy includes attaining normal body 
weight, appropriate diet with reduction of fat in-
take, particularly of saturated fats, and reduction 
of alcohol and salt intake, smoking cessation, and 
increasing regular physical activity.
4.2.1. Weight reduction and dietary recommendations
Reduction of excess body weight should be obta-
ined by reduction of caloric intake and appropriate 
diet composition (Table VIII). Patients are recom-
mended to consume vegetables, low-fat dairy pro-
ducts, fibre, and protein from plant sources, and to 
limit their saturated fat and cholesterol intake. Intake 
of fresh fruits is also recommended, although caution 
should be exercised in overweight patients and those 
with diabetes due to high sugar content in fruits. 
A Mediterranean type diet is recommended, as is 
consumption of fish at least twice a week, and fruit 
and vegetable intake should be 300–400 g per day. 
In hypertensive patients, combining exercise with the 
Dietary Approaches to Stop Hypertension (DASH) 
study diet and weight reduction resulted in more 
pronounced BP and left ventricular mass reduction 
compared to the DASH diet only.
Available data, mostly from observational studies, 
do not indicate a higher risk of incident hyperten-
sion or higher BP values in persons who regularly 
consume coffee. In contrast, consumption of energy 
drinks and foods with high fructose content should 
be avoided.
Weight reduction, and particularly reduction of 
abdominal obesity, not only results in BP lowering 
but also reduces dyslipidaemia and insulin resistance. 
It has been estimated that reducing body weight by 
10 kg contributes to SBP lowering by approximately 
5–20 mm Hg, and this BP lowering effect is more 
pronounced in obese subjects compared to those 
with near-normal body weight.
Body weight reduction may have a favourable 
effect on the effectiveness of antihypertensive drug 
therapy. The therapeutic approach to body weight 
reduction should be multidisciplinary and involve 
dietary counselling and regular exercise.
4.2.2. Salt intake
A causal relationship has been proven between salt 
intake and BP values. Excessive salt intake may con-
tribute to resistance to antihypertensive treatment.
Reduction of sodium intake to 75–100 mmol/ 
/day (4.35–5.8 gram of salt) results in BP lowering 
by an average of 2–8 mm Hg. Hypertensive patients 
should not consume more than 5 g of salt per day 
(£ 85 mmol of sodium) (Table IX). Blood pressure-
-lowering effect of reduction of sodium intake is seen 
in salt-sensitive subjects and is more pronounced 
in blacks, the elderly, and patients with diabetes, 
metabolic syndrome, and chronic kidney disease. 
Limiting salt intake allows reduction of the number 
and doses of antihypertensive drugs. Evaluation of 
sodium intake should be based on measurements 
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Table IX. Recommendations regarding salt intake in hyper-
tensive patients
Reduce salt intake from usual 9–12 g to about 5 g per day (85 mmol Na)
To achieve this target:
• discontinue using salt when preparing meals at home and at the table
• eat meals prepared from fresh, natural products
• avoid products containing sodium compounds used as preservatives
king significantly increases the global risk of ischemic 
heart disease, stroke, and peripheral arterial disease, 
particularly in hypertensive patients. Reducing smo-
king habit is an important component of cardiovascu-
lar risk reduction efforts in hypertensives (Table XI). 
Smoking status of the patient should be ascerta-
ined at each visit. Smokers should be counselled to 
quit. Medications to help quit smoking should be 
considered, including nicotine replacement therapy, 
buproprion, varenicline, and cytisine.
4.2.5. Physical activity
Appropriate physical activity is an important com-
ponent of non-drug therapy. It has been shown that 
regular exercise may reduce BP by 4–9 mm Hg. An 
increase in physical activity also helps reduce over-
weight, increase general fitness, and reduce mortali-
ty. Patients with hypertension should be advised to 
engage in at least 30 minutes of moderate dynamic 
aerobic exercise, such as jogging, brisk walking, cyc-
ling, or swimming, on 5–7 days per week. Isome-
tric exercises (to build up muscle strength without 
a dynamic component) are not recommended. Basic 
recommendations regarding increasing physical acti-
vity are summarized in Table XII.
of 24-hour urinary sodium excretion, although this 
approach may be prone to a significant error. Despite 
an inverse relationship between sodium excretion 
and total mortality found in the general population, 
no data are available to indicate that reducing large 
or moderate salt intake in hypertensives might be 
harmful. In addition, salt intake reduction in the 
TOHP study was associated with a lower risk of 
cardiovascular events.
4.2.3. Alcohol consumption
A linear relation is observed between alcohol intake 
and BP values. Increased alcohol consumption predispo-
ses to more frequent occurrence of strokes and attenuates 
the effect of antihypertensive drugs. If total elimination of 
alcohol intake is not possible, it is recommended:
•	 in men: daily alcohol consumption should be 
reduced to 20–30 g of pure ethanol;
•	 in women: daily alcohol consumption should 
be reduced to 10–20 g of pure ethanol.
Total weekly alcohol consumption should not ex-
ceed 140 g in men and 80 g in women. The following 
amounts of alcoholic beverages contain 10 g of pure 
ethanol: 250 mL of beer, 100 mL of wine, and 25 g 
of vodka (Table X).
Table X. Recommendations regarding alcohol intake in 
hypertensive patients
Increased alcohol intake predisposes to increased stroke rates and 
attenuates the effect of antihypertensive drugs
Alcohol intake should be limited to:
• 20–30 g of pure ethanol daily in men
• 10–20 g of pure ethanol daily in women
Note: 10 g of pure ethanol corresponds to 250 mL of beer, 100 mL of 
wine, and 25 g of vodka
Table XI. Recommendations regarding smoking in hyper-
tensive patients
Each patient should be asked about smoking at each visit
Active counselling should be undertaken regarding smoking cessation
Minimum anti-nicotine intervention should be performed at least 
once a year
If necessary, recommend:
• nicotine replacement therapy
• treatment with bupropione
• treatment with cytisine
• treatment with varenicline
If these measures fail, refer patients to addiction treatment centres
Weight gain should be prevented
Table XII. Basic recommendations regarding increased 
physical activity in hypertensive patients
Daily systematic exercise of moderate intensity for 30–45 minutes
Endurance exercises (walking, running, swimming) supplemented 
with resistance exercises (e.g., squatting), adjusted to age, conco-
mitant conditions, and patient preferences
Avoidance of isometric exercises (lifting heavy weights)
In patients with cardiac disease, exercise ECG testing and medically 
supervised rehabilitation may be necessary
ECG — electrocardiogram
4.2.4. Cigarette smoking
Smoking one cigarette induces a significant in-
crease in BP and heart rate that persists for more 
than 15 minutes. Evidence is also available regarding 
harmful effects of passive smoking. In addition, smo-
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4.3. Antihypertensive medications
The choice of antihypertensive medication(s) 
should take into account the effect of the drug(s) 
on other cardiovascular risk factors, the presence of 
subclinical target organ damage, cardiovascular dise-
ase, and other concomitant disease, patient age and 
gender, possibility of drug interactions and adverse 
effects, medication cost and financial situation of 
the patient, and previous physician experience with 
a given therapy. Although the benefits of antihyper-
tensive drug therapy in reducing mortality and the risk 
of cardiovascular events are largely dependent on BP 
lowering per se, some antihypertensive drug classes 
are categorized as major, and other drug classes do 
not have this status. The criterion underlying this 
distinction is the presence or absence of data from 
large clinical trials showing significant benefits of 
a given class in reducing mortality and the risk of car-
diovascular events in patients with hypertension. In 
addition, the position taken in the previous PTNT 
guidelines was upheld that the results of large hyper-
tension trials and their metaanalyses published in the 
recent years, including after 2011, along with patho-
physiological clues and pharmacologic differences, 
suggest a possibility of no class effect and/or better 
clinical utility of specific drugs within their classes, 
both major ones and others, in specific clinical si-
tuations, as indicated below when discussing drug 
classes, special patient populations, and individuali-
zation of antihypertensive drug therapy.
4.3.1. Major drug classes
In uncomplicated hypertension, and in most cases 
of complicated hypertension and hypertension with 
concomitant diseases, except for hypertension in pre-
gnancy, antihypertensive therapy should be started 
with medications from the five major drug classes 
with a proven beneficial effect on reducing cardio-
vascular mortality and/or the risk of cardiovascular 
events. These are thiazide/thiazide-like diuretics, 
beta-blockers, calcium antagonists, angiotensin-
converting enzyme inhibitors (ACE-I), and angio-
tensin II (AT1) receptor blockers or sartans (ARB). 
In accordance with the above mentioned position 
regarding within-class differences between drugs, we 
continue to prefer certain subgroups within some 
major antihypertensive drug classes (Table XIII).
4.3.1.1. Thiazide/thiazide-like diuretics
Thiazide/thiazide-like diuretics are among fir-
st-line drugs used as monotherapy, particularly in 
the elderly patients, subjects above 80 years of age 
(indapamide), and patients with a history of stro-
ke. They are also often used as a part of two-drug 
combinations, particularly in patients with con-
comitant diabetes, those with renal dysfunction 
or with coexisting symptomatic heart failure, and 
are a necessary component of three-drug combi-
nations in the treatment of more severe hyperten-
sion. Of note, full BP-lowering effect of thiazi-
de/thiazide-like diuretics is seen only after several 
days of treatment. In the recent years, some data 
have been published indicating that thiazide-like 
diuretics (chlorthalidone, indapamide) should be 
preferred due to more evidence of benefit regarding 
cardiovascular risk prevention in large-scale clinical 
trials (ALLHAT, ADVANCE, HYVET, PATS), low 
utility of hydrochlorothiazide monotherapy in cu-
rrently used low doses of 12.5–25 mg (smaller and 
shorter-lasting BP-lowering effect), and a more bene-
ficial metabolic profile of thiazide-like diuretics, al-
though the most recent metaanalysis did not confirm 
the latter difference. The two thiazide-like diuretics 
mentioned above provide a choice based on the expec-
ted diuretic effect, ranging from moderate (indapa-
mide) to large (chlorthalidone). Attention should be 
paid to possible metabolic (dyslipidemia and the risk 
of new-onset diabetes) and electrolyte disturbances 
(hypokalaemia, hyperuricaemia, and hyponatremia), 
and respective laboratory parameters should be mo-
nitored during long-term therapy with conventional 
thiazide and thiazide-like diuretics due to the fact 
that an association was observed between long-term 
benefits of these drugs and the occurrence of the 
above mentioned disturbances during treatment.
Potassium supplementation is often necessary 
during treatment with thiazide/thiazide-like diuretics. 
4.3.1.2. Beta-adrenergic receptor blockers
Use of beta-blockers in the treatment of hyper-
tension is recommended in patients with tachycardia 
and/or arrhythmia, evidence of a hyperkinetic cir-
culation, particularly in younger subjects, and with 
concomitant heart failure or coronary artery disease, 
Table XIII. Major classes of antihypertensive drugs
Five major classes of antihypertensive drugs
• with proven outcome benefits
• used as monotherapy
• recommended for combination treatment
Thiazide diuretics (preferred thiazide-like agents)
Beta-blockers (preferred vasodilatatory agents)
Calcium antagonists (preferred dihydropyridines)
Angiotensin-converting enzyme inhibitors
Angiotensin receptor blockers
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particularly after a previous myocardial infarction. 
Following oral administration, BP-lowering effect of 
beta-blockers is seen within several hours but the full 
treatment effect is evident only after several weeks. 
In the recent years, multiple controversies arose re-
garding use of beta-blockers, in particular of older 
generations, as monotherapy in patients with hy-
pertension, and thus whether beta-blockers should 
remain among the first-line drugs for the treatment 
of hypertension. In several large-scale clinical trials 
in hypertensives, conventional cardioselective beta-
-blockers (atenolol) were less effective in preventing 
cardiovascular events compared to inhibitors of the 
renin-angiotensin-aldosterone system (RAAS) and 
calcium antagonists. Metaanalyses of clinical trials 
showed a lower efficacy of these drugs in inducing re-
gression of left ventricular hypertrophy and preventing 
stroke, which may be related to their weaker effect on 
central aortic pressure. However, other metaanalyses 
showed benefits of conventional cardioselective beta-
-blockers in the treatment of hypertension in patients 
after an acute coronary syndrome, and mortality bene-
fits in hypertensive patients with chronic obstructive 
pulmonary disease and heart disease.
The position taken in the previous PTNT guide-
lines was upheld that vasodilating agents (carvedilol, 
nebivolol) should be preferred among beta-blockers 
in patients with uncomplicated hypertension. This 
has been reflected in the text of the 2013 ESH/ESC 
guidelines that noted some beneficial aspects of the 
mechanism of action of vasodilating beta-blockers. 
Due to their hemodynamic properties (smaller negati-
ve chronotropic effect and a reduction of total periphe-
ral resistance), resulting in a more favourable effect on 
central aortic pressure, these drugs should be preferred 
in uncomplicated hypertension if a beta-blocker is 
indicated. However, appropriate clinical studies wo-
uld be required to document the efficacy of vasodila-
ting beta-blockers in the prevention of cardiovascular 
events in hypertensive patients. Additional receptor-
mediated effects (alpha1-adrenergic receptor blockade 
by carvedilol, beta3-adrenergic receptor activation by 
nebivolol), beneficial effects on metabolic parameters 
and endothelial function, and the results of large-sca-
le clinical trials (GEMINI, COMET, SENIORS) all 
suggest that vasodilating beta-blockers should be pre-
ferred if a beta-blocker is indicated in hypertensives 
with diabetes or metabolic syndrome, and in those 
after cardiovascular events and with coexisting car-
diovascular disease. If it is necessary to achieve desired 
heart rate reduction (due to coexisting heart failure, 
ischemic heart disease, or aortic dissection), conven-
tional, highly cardioselective beta-blockers (bisoprolol, 
betaxolol, metoprolol succinate) may be more useful.
4.3.1.3. Calcium antagonists
An important advantage of calcium antagonists is 
their neutral metabolic effect, and thus these drugs 
are useful in combination with RAAS inhibitors in 
patients with concomitant lipid and/or carbohydrate 
metabolism disturbances. Dihydropyridines should 
be preferred as monotherapy, as much more evidence 
from large-scale clinical trials (ALLHAT, ASCOT, 
VALUE, ACCOMPLISH) is available for this sub-
group. Of note, efficacy and safety of long-acting 
dihydropyridines were shown in the elderly, inclu-
ding patients with ISH (Syst-Eur), patients with pe-
ripheral arterial disease, and those with concomitant 
chronic obstructive pulmonary disease or asthma. 
Some metaanalyses suggest high efficacy of calcium 
antagonists in the prevention of atherosclerosis, and 
clinically in the prevention of stroke, but this was not 
confirmed in secondary stroke prevention studies. 
On the other hand, metaanalyses also indicate that 
these drugs are less effective in preventing heart failu-
re and reducing proteinuria. Although most evidence 
for cardiovascular risk reduction in large-scale clinical 
trials was obtained for amlodipine, use of this drug 
is associated with a relatively high rate of leg oedema 
and thus lercanidipine and lacidipine are alternative 
long-acting but better tolerated drugs of this class.
4.3.1.4. Angiotensin-converting enzyme inhibitors and 
angiotensin receptor blockers
Both these classes of RAS inhibitors are among 
the most commonly used in the treatment of hyper-
tension and have most indications in special patient 
populations. 
Angiotensin-converting enzyme inhibitors are 
preferred in hypertension with target organ damage 
or high cardiovascular risk, particularly with coexi-
sting ischemic heart disease, heart failure or renal 
disease, in hypertension with metabolic syndrome 
and/or diabetes, and, in combination with a thiazi-
de-like diuretic, in patients with a history of stroke. 
Metaanalyses suggest additional benefits of ACEI in 
the prevention of cardiac events beyond BP lowering 
effect that may be associated with bradykinin-media-
ted effects of these drugs, particularly those with high 
tissue affinity, such as perindopril (EUROPA study). 
In the SMILE-4 study, sulfhydryl (-SH) group-con-
taining zofenopril was more effective compared to ra-
mipril in patients with post-infarction left ventricular 
dysfunction, particularly those with hypertension.
Angiotensin receptor blockers are preferred in pa-
tients with hypertension and left ventricular hyper-
trophy, concomitant renal disease (including diabetic 
nephropathy), and in those with a history of stroke, 
while in hypertensives with ischemic heart disease or 
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heart failure they are recommended as an alternative 
to ACEI if the latter are not tolerated. Some meta-
analyses suggested that ARB prevent stroke better 
than myocardial infarction.
The 2013 ESH/ESC guidelines questioned the 
clinical importance of previous suggestions regarding 
differences between ACEI and ARB in regard to car-
diovascular event prevention, based on a large 2009 
metaanalysis and the ONTARGET study which 
directly compared the effect of ramipril and telmi-
sartan on cardiovascular mortality and morbidity in 
high cardiovascular risk patients and showed no dif-
ference between these two drugs. However, three im-
portant metaanalyses were published in 2012–2014, 
focusing on different patient populations, i.e. hyper-
tensives, patients with hypertension and/or ischemic 
heart disease, and diabetic patients, that all showed 
an advantage of ACEI over ARB. The first of these 
metaanalyses suggested a special position of perindo-
pril among ACEI, particularly during combination 
therapy. Taking into account consistent results of 
these metaanalyses, it seems reasonable to conclude 
that ACEI should be preferred over ARB (with in-
dications retained for telmisartan) in patients with 
hypertension and high cardiovascular risk, i.e., with 
concomitant cardiovascular and metabolic complica-
tions, a position which has been reflected in the table 
that summarizes individualization of antihyperten-
sive drug therapy. In contrast, ACEI and ARB have 
equivalent positions in uncomplicated hypertension 
with lower cardiovascular risk.
4.3.2. Other antihypertensive drugs
Due to lack of prospective studies evaluating the 
effect on mortality and cardiovascular risk, other 
drug classes, such as alpha-blockers, aldosterone 
antagonists, loop diuretics, imidazoline receptor 
agonists, and peripheral and central sympatholytic 
drugs, are not recommended as first- and second-li-
ne antihypertensive medications. However, this does 
not preclude use of these drugs during combination 
therapy if indicated individually, and in resistant 
hypertension, usually as fourth- and fifth-line drugs.
Similarly to major antihypertensive drug classes, 
pathophysiological data, pharmacokinetic differen-
ces, and varying severity of adverse effects suggest 
better clinical utility of specific drugs also within 
other groups of antihypertensive medications (Table 
XIV). This is particularly the case for the preference 
of torasemide over furosemide among loop diuretics 
(due to more favourable pharmacokinetics), and 
eplerenone over spironolactone (less adverse effects) 
among aldosterone antagonists, although eplerenone 
is not licensed to treat uncomplicated hypertension 
in Poland. In patients with concomitant benign pro-
static hyperplasia, uroselective tamsulosin should be 
rather used if hypertension requires one- or two-drug 
therapy, while resistant hypertension would require 
doxazosin as this alpha-blocker exerts a BP-lowering 
effect.
4.4. Drug treatment algorithm
Antihypertensive drug therapy is initiated using 
one (monotherapy) or two (combined therapy) drugs 
chosen from major drug classes. Figure 3 shows the 
algorithm for the management of hypertension, and 
in particular the decision to initiate treatment with 
monotherapy or combined therapy depending on the 
severity of hypertension and the degree of BP lowe-
ring necessary to reach target BP. As target BP values 
have been unified, the algorithm continues not to 
include cardiovascular risk related to concomitant 
metabolic disturbances or cardiovascular and renal 
complications as a criterion for the choice between 
monotherapy and combined therapy.
4.4.1. Monotherapy
In monotherapy, most currently used antihy-
pertensive medications lower BP by less than 20/ 
/10 mm Hg and such an effect is observed in only 
about 50–60% of patients. Thus, therapy is initia-
ted with one drug only in grade 1 hypertension. 
It should be remembered that treatment benefits 
are mostly related to BP lowering, and thus medica-
tions characterized by a high trough-to-peak (T/P) 
ratio are preferred, particularly during monothera-
py, as they provide better 24-hour BP control and 
may be given once daily which improves patient 
compliance.
Patient’s age may serve as a pathophysiological 
clue regarding the initial drug choice in uncompli-
cated hypertension. RAAS inhibitors and beta-bloc-
kers may be effective in younger patients, in whom 
so called resistance or high-renin hypertension is 
often present, and thiazide/thiazide-like diuretics 
and calcium antagonists in older patients, who are 
more frequently characterized by volume or low-re-





Central sympatholytic agents (clonidine)
Imidazoline receptor antagonists (rilmenidine)
Peripheral sympatholytic agents (methyldopa)
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Figure 3. Management algorithm for antihypertensive drug therapy
nin hypertension. Patient gender may also be factor, 
as RAAS inhibitors should be avoided in women 
of reproductive years, and beta-blockers or calcium 
antagonist should be preferred instead.
Increasing the drug dose to the maximum dose 
exerts little additional BP lowering effect but lar-
gely increases the risk of adverse effects. Thus, if 
monotherapy using a standard drug dose does not 
produce the desired effect, adding a second drug 
has been considered the optimal next step among 
possible options.
4.4.2. Combined therapy
Most patients with hypertension require two-drug 
therapy for appropriate BP control. This is the case 
in half of patients with grade 1 hypertension and in 
most patients with higher baseline BP values. Thus, 
therapy is initiated with two drugs in grade 2 and 
3 hypertension, with an option of increasing the 
dose of one or both drugs to the maximum dose.
Major two-drug combinations used in the tre-
atment of hypertension, which are well tolerated, 
effectively lower BP, and reduce cardiovascular risk, 
include:
•	 ACEI + calcium antagonist;
•	 ACEI + thiazide/thiazide-like diuretic;
•	 ARB + thiazide/thiazide-like diuretic;
•	 ARB + calcium antagonist;
•	 ACEI + beta-blocker;
•	 calcium antagonist + beta-blocker;
•	 calcium antagonist + thiazide/thiazide-like 
diuretic.
Inclusion of the last two combinations among 
the preferred two-drug combinations in the current 
guidelines is related to the fact of their practical 
use in two important patient groups: the elderly 
(calcium antagonist + thiazide/thiazide-like diu-
retic), which was also reflected in the 2013 ESH/ 
/ESC guidelines, and young/middle-aged women 
(beta-blocker + dihydropyridine calcium antago-
nist) in whom RAAS inhibitors should be avoided.
In patients with hypertension and cardiac dise-
ase (ischemic heart disease, heart failure), the pre-
ferred combination of ACEI and beta-blocker is 
commonly used. It is the only preferred two-drug 
combination without available fixed-dose combina-
tion drug products.
In the current guidelines, the combination of beta- 
-blocker + thiazide diuretic has been considered 
acceptable due to multiple trials that documented its 
benefits versus placebo in the early era of evidence-
-based medicine, as also reflected in the 2013 ESH/ 
/ESC guidelines. It should be remembered, however, 
that such combinations are generally less effective 
in reducing cardiovascular risk (ASCOT and LIFE 
studies) and may be associated with a higher risk 
of metabolic disturbances and new-onset diabetes, 
although this risk is mitigated if the combination 
involves a thiazide-like diuretic and/or a vasodilating 
beta-blocker.
Note: RAAS inhibitors should be very cautio-
usly combined with potassium-sparing diuretics as 
this may lead to hyperkalaemia. The combination 
of ACEI + ARB is not recommended due to an 
increased risk of adverse renal effects without ad-
ditional benefits, as confirmed in the recent meta-
analyses. Non-dihydropyridine calcium antagonists 
(verapamil and diltiazem) combined with beta-bloc-
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kers predispose to bradycardia and heart failure, and 
diuretics combined with alpha-blockers predispose 
to orthostatic hypotension. The preferred two-drug 
combinations in the treatment of hypertension are 
summarized in Figure 4.
About 30% of patients require at least three drugs 
for adequate BP control. In uncomplicated hyper-
tension, the basic three-drug combination inc-
ludes a RAAS inhibitor, a calcium antagonist, and 
a thiazide/thiazide-like diuretic.
When selecting antihypertensive drugs for com-
bination therapy, the major criterion should be an 
increase of their therapeutic effect with improved 
treatment tolerance.
4.4.3. Fixed-dose combinations of antihypertensive 
drugs
Combined therapy benefits from the use of fixed-
-dose combinations of antihypertensive drugs, as 
this increases treatment effectiveness (STITCH 
and ACCOMPLISH studies), simplifies the tre-
atment scheme, and increases patient compliance 
(metaanalyses). In addition, the use of fixed-dose 
combinations is associated with an increased an-
tihypertensive efficacy compared to the algorithm 
of monotherapy-combined treatment, while use 
of lower doses minimizes the risk of dose-related 
adverse effects. Fixed-dose combinations are re-
commended to initiate antihypertensive drug the-
rapy in patients with grade 2 hypertension, as re-
flected in the management algorithm. Among the 
seven listed preferred two-drug combinations, 
six are available in Poland as fixed-dose combination 
drug products. Our decision to supplement the basic 
combinations of a RAAS inhibitor with a calcium 
antagonist or a thiazide/thiazide-like diuretic with 
two others (thiazide/thiazide-like diuretic + calcium 
antagonist and beta-blocker + dihydropyridine cal-
cium antagonist) was related, among other factors, 
to the introduction of such fixed-dose combinations 
in Poland (indapamide + amlodipine and bisoprolol 
+ amlodipine).
An interesting addition to the armamentarium 
of fixed-dose combination drug products in Poland 
has been the introduction of three-drug fixed-dose 
combinations, offering the possibility of single tablet 
therapy also in patients with higher baseline BP valu-
es, including those with grade 3 hypertension. Both 
available three-drug fixed-dose combinations (ACEI 
+ dihydropyridine calcium antagonist + thiazide-like 
diuretic and ARB + dihydropyridine calcium anta-
gonist + thiazide-like diuretic) fulfil the criteria of 
an optimal drug combination in uncomplicated hy-
pertension. Of note, analyses of randomized studies 
indicate potential benefits in terms of cardiovascular 
risk reduction for the available three-drug combina-
tion of perindopril + indapamide + amlodipine.
In the future, combined therapy using doses lower 
than standard ones available in two-and three-drug fixed
-dose combinations may prove to be an alternative ap-
proach to initiating antihypertensive therapy in patients 
with grade 1 and grade 2/3 hypertension, respectively.
Figure 4. Two-drug combinations of antihypertensive drugs 
ACE — angiotensin-converting enzyme
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Figure 5. Suggested timing of antihypertensive drug administration in relation to the 24-hour blood pressure (BP) profile
4.4.4. Chronotherapy of hypertension
Studies based on ABPM indicate that in many 
patients, additional cardiovascular risk is associated 
with masked nocturnal hypertension, non-dipping 
BP pattern, or excessive morning BP surge. Typi-
cal morning dosing of long-acting antihypertensive 
drugs may not correct these disturbances of the cir-
cadian BP profile. In these circumstances, particu-
larly with the non-dipping BP pattern or masked 
nocturnal hypertension, modification of the timing 
of antihypertensive drug administration should be 
considered, with evening drug dosing (Figure 5). 
As this approach to chronotherapy of hypertension, 
first suggested in the 2011 PTNT guidelines, has 
become popular in Poland, it should be noted that 
evening dosing of antihypertensive drugs must be 
based on evaluation by ABPM (non-dipping pat-
tern) and rather involve dosing of RAAS inhibitors. 
Evening dosing of ARB or ACEI (with a preference 
given rather to shorter-acting drugs and those tested 
in chronotherapy studies, e.g. ramipril and valsar-
tan) was associated with an improved circadian BP 
pattern, reduced microalbuminuria, and proved safe 
in large-scale clinical trials (HOPE, Syst-Eur). Unless 
nocturnal hypertension is found, evening dosing of 
antihypertensive drugs is contraindicated in patients 
with glaucoma.
5. Special patient populations
The approach to drug therapy adopted in the cur-
rent and previous guidelines gives much emphasis to 
its individualization (Tables XV and XVI).
Table XV. Individualization of drug therapy
When choosing (or avoiding) any particular drug (or drug 
combination), the following should be taken into consideration:
• Presence of cardiovascular and renal disease
• Presence of other concomitant conditions
• Presence of other cardiovascular risk factors and target organ 
damage
• Demographic factors (age, gender, race, body weight)
• 24-hour blood pressure-lowering efficacy of a drug
• Drug adverse effect profile
• Drug cost — but never at the price of lower treatment effective-
ness and tolerance
• Previous physician and patient experience with a given drug 
(drugs)
The choice of first-line therapy is important 
due to potential benefits beyond BP lowering do-
cumented in large-scale clinical trials for specific 
types of cardiovascular and renal events and me-
tabolic disturbances in hypertension, or a possibi-
lity to obtain additional benefits or avoid adverse 
effects in case of concomitant diseases. Due to 
widespread use of combination therapy, recom-
mendations regarding individualization of antihy-
pertensive drug therapy also extend to second-line 
drugs in specific clinical scenarios. Specific indi-
cations for and contraindications to different drug 
classes are shown in Tables XVI and XVII, and 
indications for the use of different drug combina-
tions or fixed-dose combination drug products are 
shown in Figure 6.
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Table XVI. Preferred first (I) and second (II) choice antihypertensive drug classes in specific conditions
Clinical condition Preferred first and second choice drugs
TD BB CA-dhp CA-ndhp ACEI ARB AA LD MD
Left ventricular hypertrophy         I I
Ischemic heart disease   I II A II B I 1 II C 2 II D
Heart failure II I 3     I II C 4 II II
Permanent atrial fibrillation   I   I
Tachyarrhythmias   I
Aortic dissection I
Peripheral arterial disease I I
Previous stroke I 5       II I
Metabolic syndrome     II II I I
Diabetes II 5   II   I I
High-risk patients (multiple cardiovascular 
and metabolic complications)
I 6 II C 7
Gout      II   I  I 8
Hypertension in the elderly I   I   II II
Hypertension above 80 years of age I 9       II
Isolated systolic hypertension I   I   II II
Albuminuria/proteinuria     II II I I
Diabetic/non-diabetic nephropathy         I I
Chronic kidney disease         I I   II
Pregnancy   II 10 II 11 II 12         I
Erectile dysfunction   II 13  II   I I
Asthma/chronic obstructive pulmonary 
disease
    I     I
Glaucoma   I
I — first choice drug
II — second choice drug
A — with angina
B — with beta-blocker intolerance
C — with angiotensin-converting enzyme inhibitor intolerance
D — after myocardial infarction
1 — preferred agents: perindopril, ramipril, zofenopril
2 — preferred agents: telmisartan and valsartan
3 — only carvedilol, bisoprolol, metoprolol XR/CR, nebivolol
4 — preferred agents: candesartan and valsartan
5 — preferred agent: indapamide
6 — preferred agents: perindopril, ramipril
7 — telmisartan has the first-choice status
8 — preferred agent: losartan 
9 — only indapamide
10 — preferred agent: labetalol (poor availability in Poland), of other beta-blockers only metoprolol
11 — only nifedipine (extended release preparation preferred)
12 — only verapamil
13 — only nebivolol
D — thiazide/thiazide-like diuretics
BB — beta-blockers
CA-dhp — dihydropyridine calcium antagonists
CA-ndhp — non-dihydropyridine calcium antagonists
ACEI — angiotensin-converting enzyme inhibitors
ARB — angiotensin receptor blockers
AA — aldosterone antagonists
LD — loop diuretics
MD — methyldopa
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Table XVII. Absolute and relative contraindications to specific antihypertensive drug classes
Drug class Absolute contraindications Relative contraindications
Diuretics Gout (thiazides) Metabolic syndrome
Glucose intolerance
Hyponatremia < 130 mmol/L
Pregnancy
Beta-blockers Asthma
Grade 2 or 3 atrioventricular block 
Chronic obstructive pulmonary disease
Metabolic syndrome
Glucose intolerance
Athletes and physically active patients
Dihydropyridine calcium antagonists Tachyarrhythmias
Heart failure
Non-dihydropyridine calcium antagonists (ver-
apamil/diltiazem)
Grade 2 or 3 atrioventricular block 
Heart failure
Bradycardia < 50 bpm
Chronic constipation (verapamil)
Angiotensin-converting enzyme inhibitors Pregnancy
Hyperkalaemia > 5.0 mmol/L
Bilateral or single kidney renal artery stenosis
Transplant renal artery stenosis
History of angioneurotic edema
Angiotensin receptor blockers Pregnancy
Hyperkalaemia > 5.0 mmol/L
Bilateral or single kidney renal artery stenosis
Aldosterone antagonists Transplant renal artery stenosis
Chronic kidney disease (eGFR < 30 mL/min)
Hyperkalaemia > 5.0 mmol/L
Pregnancy
Figure 6. Preferred choices of combined therapy/fixed-dose combination products and intensification of antihypertensive drug therapy  
in relation to concomitant conditions  
ACEI — angiotensin-converting enzyme inhibitor; BP — blood pressure; RAAS — renin-angiotensin-aldosterone system
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Table XVIII. Antihypertensive treatment strategies in the elderly
Drug therapy to reduce SBP to between 150 and 140 mm Hg is recommended in patients aged 65–80 years with grade 2–3 hypertension
In patients > 80 years with grade 2–3 hypertension, drug therapy to reduce SBP to between 150 and 140 mm Hg is recommended, provided 
the patient is in a good physical and mental condition
In patients aged 65–80 years with grade 1 hypertension, drug therapy with a target SBP < 140 mm Hg may be considered if the treatment is 
well tolerated
In patients who reach 80 years of age, continuation of previous antihypertensive therapy may be considered regardless of on-treatment BP values
In patients > 80 years with grade 1 hypertension, drug therapy is not recommended
In the elderly, initial drug doses should be lower, and subsequent therapy intensification should be more cautious due to a higher risk of adverse 
effects (hypotension)
Due to a reduced intellectual capacity of the elderly, treatment should be simplified, with frequent use of fixed-dose combination drug products
All major drug classes may be used, with some preference of thiazide/thiazide-like diuretics and dihydropyridine calcium antagonists, and thera-
py intensification using a RAAS inhibitor
In the elderly with isolated systolic hypertension, thiazide/thiazide-like diuretics and dihydropyridine calcium antagonists are preferred
In patients > 80 years, the preferred first line drug is indapamide, and the second line drug is ACE inhibitor
ACE — angiotensin-converting enzyme; BP — blood pressure; RAAS — renin-angiotensin-aldosterone system; SBP — systolic blood pressure
5.1. Hypertension in the elderly
Large clinical trials and metaanalyses indicate that 
antihypertensive therapy in patients above 65 years 
of age significantly reduces the rate of strokes, heart 
failure incidence, and cardiovascular mortality. Pa-
tients with SBP ≥ 160 mm Hg were recruited to the-
se studies, and SBP was lowered below 150 mm Hg 
but not below 140 mm Hg. Thus, antihypertensive 
therapy may be clearly recommended in the elderly 
patients with grade 2 hypertension, in whom SBP 
should be lowered to 140–150 mm Hg. However, 
due to rational reasons and the fact that persons abo-
ve 65 years of age constituted a significant propor-
tion of patients in many clinical trials, antihyperten-
sive therapy should also be considered in those with 
SBP above 140 mm Hg, aiming for target SBP below 
140 mm Hg, if the patient is in a good overall con-
dition and tolerates the therapy well. In patients abo-
ve 80 years of age, based on the results of the HYVET 
study, it may be generally recommended to initiate 
antihypertensive therapy if SBP is above 160 mm Hg, 
aiming for target SBP below 150 mm Hg. However, 
due to differences in the general health condition 
of these individuals, the decision to initiate therapy 
should be individualized, and BP lowering should be 
gradual and carefully monitored by the physician. In 
the elderly patients with concomitant disease, such 
as coronary artery disease, chronic kidney disease or 
diabetes, specific target BP values accepted for these 
clinical conditions should apply.
Benefits of antihypertensive therapy in the elderly 
are comparable to those obtained in younger age gro-
ups. However, due to a reduced adaptive capacity of 
the cardiovascular system and the risk of orthostatic 
hypotension, therapy should be more cautious, and 
target BP values should be reached more gradually. 
Due to the risk of orthostatic hypotension and falls, 
BP in the elderly hypertensive should be measured 
after 1 and 3 minutes of standing (orthostatic te-
sting) in the following situations:
•	 therapy initiation;
•	 treatment change;
•	 history of falls;
•	 dizziness or near-fainting;
•	 concomitant diabetes.
Although the basic principles of non-drug therapy 
in the elderly hypertensives are the same as in youn-
ger subjects, limitations due to impaired mobility 
and reduced fitness, precluding regular exercise, sho-
uld be borne in mind.
All major classes of antihypertensive medications 
were tested in large-scale clinical trials in the elderly 
patients, and recent metaanalyses do not indicate 
any differences in the efficacy of antihypertensive 
medications in relation to the patient’s age. Ho-
wever, as dictated by the clinical experience, and 
if there are no specific indications to individualize 
therapy otherwise, first-line drugs are thiazide/thia-
zide-like diuretics and dihydropyridine calcium an-
tagonists or their combination. In clinical trials in 
patients with the most common type of hyperten-
sion in the elderly, ISH, only diuretics and calcium 
antagonists with a possible addition of a RAAS 
inhibitor were used. In patients above 80 years 
of age, available studies (HYVET) indicate that 
the therapy should be initiated with a long-acting 
thiazide-like diuretic (indapamid), with a possible 
addition of an ACEI (Table XVIII).
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5.2. Hypertension in women
In the Blood Pressure Lowering Treatment Tria-
lists’ Collaboration metaanalysis that compared be-
nefits of antihypertensive therapy in men and wo-
men, both similar BP-lowering effect and similar 
treatment outcomes were noted in both genders, 
with no differences in response to different class of 
antihypertensive medications. In women who plan 
pregnancy or are potentially able to conceive, use of 
ACEI and ARB should be avoided due to potential 
teratogenic effects of these drugs.
Hypertension is not an absolute contraindication 
for the use of hormonal replacement therapy or oral 
contraception. If these therapies are used, BP should 
be measured at each visit and hypertension should be 
treated according to the general management prin-
ciples.
The likelihood of BP increase in hypertensive 
women who receive hormonal replacement therapy 
during menopause is small, but hormonal replace-
ment therapy and selective oestrogen receptor mo-
dulators should not be use for primary or secondary 
prevention of cardiovascular events.
Use of oral contraceptives is associated with 
a small but significant BP increase and development 
of hypertension. However, most studies evaluated the 
effect of older generation contraceptives that conta-
ined a higher oestrogen dose than those currently 
used. Data are lacking regarding the effect of newer 
hormonal contraceptive methods (vaginal and trans-
dermal) on BP but an association was confirmed be-
tween newer contraceptive methods and an increased 
risk of venous thrombosis. Progestin-only containing 
oral contraceptives (minipills) are not considered 
contraindicated in mild and moderate hypertension 
but they constitute a minor proportion of currently 
used oral contraceptives. 
5.3. Hypertension in pregnant women
There are two major types of hypertension in pre-
gnancy:
•	 chronic (preexisting) hypertension — BP ≥ 
140/90 mm Hg before pregnancy or developing 
before 20 weeks of gestation and persisting bey-
ond 12 weeks after delivery;
•	 gestational (pregnancy-induced) hypertension 
— developing after 20 weeks of gestation and 
resolving within 12 weeks after delivery.
Preeclampsia is a multiorgan dysfunction syndro-
me complicating hypertension in pregnancy, with 
a serious prognosis for the pregnancy itself and future 
cardiovascular risk of the woman. It usually develops 
between 20 weeks of gestation and 3 days after de-
livery, with worse pregnancy outcomes if it occurs 
early, particularly before 32 weeks of gestation. It is 
defined as:
•	 gestational (pregnancy-induced hypertension) 
— new-onset BP ≥ 140/90 mm Hg (mean of ≥ 
2 measurements within ≥ 4 hours, and if BP ≥ 
160/110 mm Hg — within minutes); and
•	 any of the following findings occurring de novo: 
proteinuria (≥ 300 mg/24 hours, protein/creati-
nine ratio ≥ 0.3, protein 1 + or more on reagent 
strip), low platelet count (< 100,000/uL), renal 
function worsening (serum creatinine > 1.1 mg/dL 
or doubling of the serum creatinine level in chro-
nic kidney disease), hepatic dysfunction (increase 
in alanine transaminase/aspartate transaminase 
level to 2 times the upper limit of normal), pul-
monary oedema, central nervous system signs or 
symptoms, vision disturbances. 
Preeclampsia is likely related to placental dysfunc-
tion and thus develops mostly in the second half of 
pregnancy in pregnancy-induced hypertension but 
may also occur in women with preexisting hyper-
tension, in whom BP elevation with other features 
of preeclampsia is seen after 20 weeks of gestation 
— this is diagnosed as preeclampsia superimposed 
upon chronic hypertension.
If hypertension was first found after 20 weeks of 
gestation, without other evidence of preeclampsia, 
and previous BP values are unknown or uncertain, 
antenatally unclassified hypertension should be 
diagnosed and the diagnosis should be verified at or 
beyond 12 weeks after delivery.
Other serious complications of hypertension in 
pregnancy include the HELLP syndrome (clotting 
abnormalities, hepatic dysfunction, and low plate-
let count) and eclampsia, or symptoms of central 
nervous system dysfunction.
Is secondary hypertension (renal artery stenosis 
or phaeochromocytoma) is suspected in a pregnant 
woman, appropriate investigations and treatment 
should be undertaken before the third trimester, and 
the optimal approach would to be to perform full 
diagnostic work-up for secondary hypertension be-
fore pregnancy.
The principles of antihypertensive treatment in 
pregnant women are summarized in Table XIX.
5.4. Hypertension in patients with metabolic 
syndrome
Hypertension or high normal BP is a frequent 
component of metabolic syndrome. Recommending 
lifestyle changes, particularly body weight reduction 
and increased physical activity, is very important in 
all individuals with metabolic syndrome as the first 
and foremost intervention in the management of 
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Table XIX. Antihypertensive treatment strategies in pregnant women
In all pregnant women, modified non-drug treatment is recommended (no alcohol intake and smoking, limitation of physical activity), without limita-
tion of salt intake
Drug treatment is recommended if BP is ≥ 150/95 mm Hg in pregnant women with uncomplicated and asymptomatic preexisting hypertension,  
and ≥ 140/90 mm Hg in women with pregnancy-induced hypertension (regardless of the presence of proteinuria), and complicated, symptomatic, 
or secondary preexisting hypertension
Target BP in pregnant women is < 140/90 mm Hg. Frequent evaluation by ABPM is recommended
BP values ≥ 170/110 mm Hg should be considered an indication for hospital admission
In pregnant women with hypertension, the preferred drug is methyldopa. Labetalol* may be added in the first trimester, and metoprolol tartrate  
and/or calcium antagonist (nitrendipine or nifedipine SR* or verapamil) may be added starting from the second trimester
Hydralazine* may be considered as a fourth-line drug. Continuation of pre-pregnancy treatment with a thiazide diuretic is controversial (harmful 
effects of hypovolaemia in preeclampsia and an increased risk of schizophrenia in children)
In severe hypertension that cannot be controlled by oral drugs, nitroglycerin by intravenous infusion, intravenous labetalol, or intravenous urapidil 
may be used. Seizure prevention is also necessary using intravenous magnesium sulphate that also has a BP-lowering effect
The following drugs are absolutely contraindicated during pregnancy and breastfeeding due to observed or potential teratogenic effects: ACE inhibi-
tors, ARB, renin inhibitors, aldosterone antagonists, and diltiazem
All antihypertensive drugs are secreted to breast milk, and thus the same drugs are recommended during lactation as during pregnancy
Hypertension is an indication for acetylsalicylic acid 75–150 mg daily starting from 12 weeks of gestation until delivery to prevent preeclampsia
ABPM — ambulatory blood pressure monitoring; ACE — angiotensin-converting enzyme; ARB — angiotensin receptor blockers; BP — blood pressure 
*Drugs not routinely available in Poland, may be imported individually by a physician prescription
hypertension. The aim is to reduce body weight by 
7–10% over 6–12 months by modest reduction of 
caloric intake (by 500–1000 kcal per day) which is 
usually more effective than a more rigorous diet.
Antihypertensive drug therapy is recommended 
for BP ≥ 140/90 mm Hg, with the aim to lower BP 
below 140/90 mm Hg. Currently, no evidence from 
outcome trials justifies initiation of drug treatment in 
patients with metabolic syndrome and high normal 
BP. Metabolic syndrome is associated with a high 
risk of developing diabetes, and thus the effect of an-
tihypertensive drugs on glucose metabolism should 
be taken into consideration when choosing between 
drug classes. Drug therapy should be initiated with 
RAAS inhibitors which delay development of diabe-
tes, with the addition of a calcium antagonist if ne-
cessary. Beta-blockers and conventional thiazide diu-
retics should be avoided in patients with metabolic 
syndrome. If drugs from these classes are indicated, 
vasodilating beta-blockers and thiazide-like diuretics 
should be chosen. When prescribing a diuretic, 
a potassium-sparing preparation should be conside-
red, as hypokalaemia worsens glucose tolerance.
5.5. Hypertension in diabetic patients
The prevalence of hypertension among diabetic 
patients is increased compared to the general po-
pulation. Nighttime hypertension is common and 
often masked. Thus, ABPM is recommended in each 
diabetic patient.
Blood pressure should also be measured in the 
standing position in case of symptoms suggesting 
hypotension during therapy intensification.
In patients with hypertension and diabetes, an-
tihypertensive drug therapy is typically recommen-
ded when BP is > 140/90 mm Hg. No evidence is 
available from outcome clinical trials that would 
justify initiating drug therapy in patients with dia-
betes and high normal BP. Recent analyses indicate 
that optimal reduction of the global cardiovascular 
risk in most patients with hypertension and diabetes 
is obtained by lowering BP below 140/85 mm Hg. 
The change of the target DBP value has been based 
on an analysis of HOT and UKPDS study findin-
gs. Benefits of BP lowering below 130/80 mm Hg 
in diabetic patients have not been confirmed in 
the ACCORD and INVEST studies and are de-
batable also in patients with concomitant diabetic 
nephropathy.
Effective BP control in diabetic patients is dif-
ficult and thus these patients more often require 
combined antihypertensive drug therapy. Due to 
a proven nephroprotective effect of RAAS inhibitors, 
ACEI or ARB should be an invariable component of 
combination therapy and the preferred choice in mo-
notherapy. When choosing between ACEI and ARB 
in diabetic patients, results of the most recent meta-
analysis of studies performed in this group of patients 
may be taken into consideration, showing a greater 
long-term cardioprotective effect of ACEI. For com-
bined therapy, first choices should include an ACEI 
with a calcium antagonist (ACCOMPLISH) or 
a thiazide-like diuretic (ADVANCE). Recently repor-
ted results of the ADVANCE ON study showed 
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Table XX. Antihypertensive treatment strategies in patients with diabetes
Antihypertensive drug therapy is recommended in patients with grade 1–3 hypertension
Target BP in patients with diabetes is < 140/85 mm Hg
The presence of proteinuria does not modify target BP
In diabetes, RAAS inhibitors (ACE inhibitors and ARB) are recommended due to a greater nephroprotective effect
Combined drug treatment is more often required to obtain good BP control
Thiazide diuretics (thiazide-like agents are preferred) and dihydropyridine calcium antagonists are recommended in combination with a RAAS inhibitor
It is not recommended to combine two RAAS inhibitors
Statin therapy is recommended
Acetylsalicylic acid may be considered
ACE — angiotensin-converting enzyme; ARB — angiotensin receptor blockers; BP — blood pressure; RAAS — renin-angiotensin-aldosterone system
for the first time that antihypertensive therapy with 
a fixed-dose combination (perindopril + indapamide) 
may yield long-term (10 years) outcome benefits.
Concomitant administration of two RAAS in-
hibitors (also including the renin inhibitor) should 
be avoided due to a higher risk of hyperkalaemia 
and worsening of renal function (ONTARGET and 
ALTITUDE studies).
The management of patients with hypertension 
and diabetes should be particularly targeted at im-
provement of all cardiovascular risk factors. This 
means a strong indication for a statin, and the need 
to consider possible benefits of acetylsalicylic acid 
(ASA) (Table XX).
5.6. Hypertension in patients with chronic 
kidney disease
Observational studies show a direct correlation be-
tween BP values and development of chronic kidney 
disease. Protection from further progression of renal 
disease requires strict BP control (< 140/90 mm Hg) 
and reducing proteinuria as much as possible. Lowe-
ring BP below 130/80 mm Hg to delay albuminuria 
is questionable (ROADMAP study), and in patients 
with hypertension and concomitant nephropathy 
with large proteinuria it remains a domain of ne-
phrologists.
Compared to other classes of antihypertensive 
medications, ACEI and ARB are more effective 
at reducing proteinuria and delaying progression 
of renal disease, and thus are indicated in patients 
with moderately reduced glomerular filtration rate 
and/or proteinuria. Therapy should be started 
with low doses that are later cautiously increased 
to moderate ones, with monitoring of creatinine 
and potassium levels. Reduction of baseline eGFR 
by 30% during the first 4–12 weeks of therapy 
should be considered acceptable. ACEI and ARB 
should not be used in patients with acute kidney 
injury, and initiation of these drugs is not recom-
mended, unless supervised by a nephrologist, in 
patients with chronic kidney disease and eGFR 
below 30 mL/min/1.73 m2.
Combined therapy using several antihyperten-
sive drugs is usually required to reach target BP. 
Based on the results of the ACCOMPLISH study, 
it was shown that a combination of an ACEI with 
a calcium antagonist rather than a thiazide diuretic 
is more effective at preventing doubling of serum 
creatinine level and development of end-stage renal 
disease. The type and dose of a diuretic should be 
adjusted to renal function. Thiazide and thiazide-like 
diuretics should not be used in patients with eGFR 
below 30 mL/min, and loop diuretics should be used 
instead. Doses of loop diuretics should be increased 
with worsening of renal function.
In advanced chronic kidney disease, mineralocor-
ticoid receptor antagonists are not recommended, 
particularly in combination with ACEI/ARB, due to 
a risk of renal function worsening and development 
of hyperkalaemia. If mineralocorticoid receptor an-
tagonists are used in this patient group, strict moni-
toring of potassium level is required. Combining two 
RAAS inhibitors is also not recommended despite 
potentially higher effectiveness in reducing prote-
inuria. The latter two therapeutic options should 
remain a domain of nephrologists.
5.7. Hypertension complicated by ischaemic 
heart disease
Hypertension is an important factor in the path-
ogenesis of ischemic heart disease (accelerated athe-
rosclerosis, left ventricular hypertrophy). In patients 
with hypertension in whom BP is lowered below 
140/90 mm Hg, a clear reduction of the cardio-
vascular event rate is seen compared to patients with 
on-treatment BP values above 140/90 mm Hg, regar-
dless of the drug classes used.
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Table XXI. Antihypertensive treatment strategies in patients with heart disease
Target BP in patients with heart disease is < 140/90 mm Hg, and the likelihood of a clinical J-curve effect is particularly high in this patient group
Preferred antihypertensive drugs in patients with ischemic heart disease, and particularly after a myocardial infarction, are ACE inhibitors and beta-
-blockers, and in patients with angina also calcium antagonists
Preferred antihypertensive drugs in patients with heart failure are ACE inhibitors and beta-blockers, followed by aldosterone antagonists, and diu-
retics in symptomatic patients
In patients with ischemic heart disease and/or heart failure, ARB are alternative second choice drugs in case of ACE inhibitor intolerance
In patients with atrial fibrillation with rapid ventricular response, beta-blockers and possibly non-dihydropyridine calcium antagonists are recom-
mended as antihypertensive drugs
Every hypertensive patient with heart disease requires statin and acetylsalicylic acid
Every hypertensive patient with atrial fibrillation requires antithrombotic treatment, preferentially with a novel oral anticoagulant
In patients with a risk of de novo or recurrent atrial fibrillation, ACE inhibitors or ARB may be considered for antihypertensive drug therapy, and eple-
renone may be considered in patients with concomitant heart failure
ACE — angiotensin-converting enzyme; ARB — angiotensin receptor blockers; BP — blood pressure
Long-term data from the INVEST study showed 
that in both patients with strict BP control (SBP 
< 130 mm Hg) and those with uncontrolled BP 
(SBP > 140 mm Hg), outcomes were worse than in 
patients with SBP 130–140 mm Hg, confirming the 
existence of the J curve in this patient group.
Although optimal BP reduction is the most im-
portant factor, recommended antihypertensive drugs 
in patients with concomitant ischaemic heart disease 
are ACEI (preferred drugs of this class are perindopril 
— EUROPA study, ramipril — HOPE study, and 
zofenopril — SMILE 4 study) and beta-blockers, 
particularly in patients after a myocardial infarction. 
If angina is present, calcium antagonists are also 
used. In patients with concomitant ischaemic heart 
disease, ARB are second-choice drugs (preferred ones 
are telmisartan — ONTARGET study, and in pa-
tients after a myocardial infarction also valsartan — 
VALIANT study) in case of ACEI intolerance, based 
on the results of multiple metaanalyses comparing 
these two drug classes in regard to reduction of the 
risk of death and cardiac events.
5.8. Hypertension complicated by heart failure
Along with ischemic heart disease, hypertension 
is one of the two major causes of heart failure. It 
often leads to left ventricular diastolic dysfunction 
and heart failure with preserved ejection fraction. 
It is also the most important modifiable risk fac-
tor for the development of heart failure, and thus 
preventing heart failure involves use of antihyper-
tensive drugs. Diuretics, beta-blockers, ACEI, and 
ARB were shown to be beneficial in the prevention 
of heart failure, while calcium antagonists are less 
effective in this regard.
In advanced heart failure, hypertension becomes 
less problematic due to reduction of cardiac output 
in this condition, and higher BP values are pro-
gnostically favourable. Any antihypertensive therapy 
should be undertaken with consideration of the cu-
rrent guidelines on the management of heart failure, 
which means that the preferred drugs in this patient 
group are beta-blockers (only carvedilol, bisoprolol, 
metoprolol XR/CR, and nebivolol), ACEI (drugs 
studied in postinfarction left ventricular dysfunction 
include lisinopril, ramipril, trandolapril, and zofeno-
pril), and aldosterone antagonists (eplerenone is the 
preferred drug). ARB are second-choice drugs in case 
of ACEI intolerance (preferred drugs of this class are 
candesartan and valsartan).
Diuretics are recommended in patients with cli-
nical evidence of left- or right-sided heart failure. 
The preferred drugs are thiazide-like diuretics with 
greater natriuretic effect (chlorthalidone) and loop 
diuretics, which induce an even stronger natriuretic 
effect. Among the latter, torasemide is characterized 
by greater bioavailability, better absorption, and lon-
ger half-life compared to furosemide, and exerts an 
additional anti-aldosterone effect, which translated 
to increased clinical benefits observed in the non-
-randomized TORIC study (Table XXI).
5.9. Hypertension complicated by atrial 
fibrillation
Hypertension is the most common condition co-
existing with atrial fibrillation, and it is conside-
red a reversible cause of this arrhythmia. In patients 
with atrial fibrillation with rapid ventricular rate, 
beta-blockers and non-dihydropyridine calcium an-
tagonists are recommended. In patients with hyper-
tension who are at risk of de novo atrial fibrillation, 
ACEI or ARB should be considered, although studies 
that evaluated reduction of the risk of recurrent atrial 
fibrillation during treatment with these drugs yielded 
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contradictory results. In hypertension complicated 
by ischemic heart disease, the risk of atrial fibrillation 
recurrence is probably reduced by any effective anti-
hypertensive drug, and if heart failure is present, the 
risk is reduced by eplerenone.
Each patient with hypertension and permanent or 
recurrent atrial fibrillation requires anticoagulation, 
preferably using oral anticoagulants other than vita-
min K antagonists (dabigatran, rivaroxaban, apixa-
ban), to prevent stroke. In patients using anticoagu-
lants, good BP control is particularly important to 
reduce the rate of bleeding events associated with 
anticoagulant therapy.
5.10. Hypertension and prevention of stroke
Regardless of the type of therapy, effective BP 
lowering reduces stroke risk more effectively than the 
risk of ischemic heart disease. Metaanalyses indicate, 
however, that beta-blockers are less effective and cal-
cium antagonists are more effective at reducing stroke 
risk compared to other antihypertensive drug classes.
Long-term after stroke or a transient ischemic 
attack (TIA), the goal of therapy should be normali-
zation of BP (target BP < 140/90 mm Hg should be 
reached slowly, and provided that treatment is well 
tolerated). The reported data indicate efficacy of thia-
zide-like diuretics (indapamide in the PATS study 
and combined with perindopril in the PROGRESS 
study) and ARB (eprosartan in the MOSES study) 
in the secondary prevention of stroke. In contrast, 
the effect of antihypertensive drug therapy on the 
severity of vascular dementia has not been documen-
ted. During each visit, BP should be measured in the 
standing position to avoid excessive BP falls.
Due attention should also be paid to other basic 
elements of secondary stroke prevention, such as 
lifestyle modification and treating risk factors, anti-
coagulation, use of antiplatelet agents, and surgical 
treatment of carotid artery stenosis.
In the acute phase of stroke, hypertension should 
only be treated if SBP exceeds 220 mm Hg or DBP 
exceeds 120 mm Hg, and the drug if choice in these 
circumstances is labetalol (or, if it is unavailable, in-
travenous agents with medium duration of action). 
BP should be slowly reduced to values not lower than 
180/110 mm Hg.
In the SCAST study, no significant effect of an-
tihypertensive drug therapy in the acute phase of 
stroke was found on cardiovascular events, including 
recurrent stroke.
Fibrinolytic therapy may be used if BP is lower 
than 185/110 mm Hg. On the second day after stro-
ke, antihypertensive therapy may be initiated if BP is 
higher than 180 and/or 120 mm Hg (Table XXII).
5.11. Other concomitant conditions
5.11.1. Hypertension with sexual dysfunction
Erectile dysfunction is more common in hyper-
tensives than in individuals with normal BP values. 
Sexual dysfunction is considered an independent 
cardiovascular risk factor and a possible marker of 
atherosclerosis.
Multiple studies showed that antihypertensive 
drug therapy using older generation diuretics and 
beta-blockers increases the risk of erectile dysfunc-
tion in men. Compared to these drugs, newer anti-
hypertensive drug classes, i.e. ARB and ACEI, have 
a neutral or even beneficial effect on erectile function. 
In contrast to conventional beta-blockers, nebivolol 
exerts a vasodilatatory effect related to nitric oxide 
release. Several studies showed that nebivolol may 
have a more beneficial effect on erectile dysfunction 
in men compared to other beta-blockers.
5.11.2. Hypertension and chronic lung disease
No studies compared the effect of antihypertensi-
ve therapy using different drug classes on long-term 
outcomes in patients with concomitant chronic obs-
tructive pulmonary disease (COPD).
However, knowledge of pharmacologic properties 
and adverse drug effect registries indicates that cal-
Table XXII. Antihypertensive treatment strategies in stroke patients
Target BP in patients after a stroke or TIA is < 140/90 mm Hg. BP should be reduced slowly, with target values reached about 2 weeks after the 
acute event, provided that the treatment is well tolerated
Antihypertensive drug therapy for the secondary prevention of stroke should be based on a thiazide-like diuretic with a possible addition of an ACE 
inhibitor, or based on an ARB
In the elderly patients after a stroke or TIA, somewhat higher target BP may be considered
Other major components of secondary prevention are indicated, such as lifestyle changes and treatment of risk factors, anticoagulant and antiplate-
let treatment, and surgical treatment of carotid artery disease (if indicated)
In the acute phase of stroke, treatment of hypertension is indicated only for BP > 220/120 mm Hg
ACE — angiotensin-converting enzyme; ARB — angiotensin receptor blockers; BP — blood pressure; TIA — transient ischemic attack
arterial hypertension 2015, vol. 19, no. 2
78 www.nt.viamedica.pl
cium antagonists and ARB may be considered safe 
antihypertensive drugs in patients with COPD. Cau-
tion is required when using ACEI (cough inducing 
bronchospasm) and beta-blockers (bronchospasm). 
If a drug from the latter class is required, its choice 
must be carefully dictated by cardioselectivity or ad-
ditional protective properties, and attention must be 
paid to the recommended dose to minimize the effect 
on lung ventilation parameters. Cardioselective beta-
-blockers were found to reduce mortality among pa-
tients with COPD and concomitant cardiac disease.
5.11.3. Hypertension and glaucoma
The safest antihypertensive drugs that are not as-
sociated with a risk of glaucoma incidence and pro-
gression are beta-blockers.
Among the risk factors for glaucoma, in addition 
to high BP, an increasing attention has been paid 
to systemic hypotension which may lead to redu-
ced perfusion of the optic disc and induce glauco-
ma lesions. It seems that systemic hypotension is 
a much more important risk factor for progression 
of visual field defects than hypertension. Thus, over-
ly aggressive antihypertensive therapy may lead to 
progression of glaucoma. Most importantly, adverse 
effects of antihypertensive therapy include excessive 
nocturnal BP fall with secondary reduction of ocu-
lar perfusion. In patients with glaucoma, evening 
dosing of antihypertensive drugs is contraindicated 
unless ABPM shows very high BP values during 
the night.
5.11.4. Hypertension and gout
The preferred choice for antihypertensive therapy 
in patients with concomitant gout is losartan, as 
this drug reduces hyperuricaemia, which might be 
of importance for the reduction of cardiovascular 
risk (LIFE study), but there are no contraindica-
tions for other ARB, ACEI, and calcium antago-
nists in patients with hyperuricaemia. In contrast, 
drugs that increase serum acid level, mostly thiazi-
de/thiazide-like diuretics and beta-blockers, are not 
recommended. Allopurinol, which is used for lon-
g-term therapy of gout, may also be considered in 
hypertensives with asymptomatic hyperuricaemia, 
particularly those with cardiovascular disease, due 
to a proven beneficial effect of this drug on the 
improvement of endothelial function and aortic 
compliance.
5.11.5. Hypertension and benign prostatic hyperplasia
When treating hypertension in men with beni-
gn prostatic hyperplasia, the general principles of 
antihypertensive therapy in the elderly using major 
drug classes should apply, and the previous recom-
mendation to initiate therapy with an alpha-blocker 
has been abandoned after the ALLHAT study. The 
decision to use an alpha1-adrenergic receptor anta-
gonist to improve micturition should be made by an 
urologist, with consideration of uroselective drugs 
(e.g., tamsulosin) for better cardiac safety in patients 
on established antihypertensive therapy. Non-selecti-
ve alpha1-blockers (e.g., doxazosin) are among useful 
third- and fourth-line antihypertensive drugs, par-
ticularly in resistant hypertension (ASCOT study).
5.11.6. Hypertension and psoriasis
The prevalence of hypertension in patients with 
psoriasis is increased compared to the general popu-
lation, as is resistance to treatment. The pathogenesis 
of hypertension in patients with psoriasis is related, 
among other factors, to systemic inflammation. Beta-
-blockers should be avoided in hypertensives with 
psoriasis and no concomitant ischemic heart disease, 
as these drugs may worsen psoriasis.
5.11.7. Hypertension in the perioperative period
Preoperatively, it is not desirable to aim for full 
BP normalization by intensifying previous therapy. 
Target BP values may be in the range of 140–160/ 
/90–100 mm Hg (due to an additional BP-lowering 
effect of anaesthetics).
Previous antihypertensive drug therapy may be 
generally continued, with usual morning dose of 
BP-lowering drugs. If possible, withholding diu-
retics 2–3 days before a major surgery should be 
considered (due to potential adverse effects related 
to fluid loss and hypokalaemia), and maybe also 
RAAS inhibitors on the day of the surgery (with 
the last dose taken on the day before the surgery). 
In the recent years, controversies have arisen aro-
und the use of beta-blockers in the perioperative 
period. Potential benefits of these drugs are limited 
to patients with a history of myocardial infarction 
or with heart failure, and thus patient populations 
in which long-term use of beta-blockers is indi-
cated anyway. In other patients, initiating beta-
-blocker therapy, particularly several days before 
the surgery, may be associated with an increased 
mortality risk. In the recent ESC guidelines, more 
consideration has been given to perioperative sta-
tin than beta-blocker use.
5.12. Resistant hypertension
Resistant hypertension is defined as BP values 
≥ 140/90 mm Hg during appropriate combination 
therapy with 3 drugs (including a diuretic) in adequ-
ate doses.
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Table XXIII. Antihypertensive treatment strategies in patients with resistant hypertension
Pseudoresistance should be excluded and correctable causes of treatment resistance should be eliminated before institution of additional therapy
In patients who are unsuccessfully treated with a RAAS inhibitor, diuretic, and calcium antagonist in maximal doses, an aldosterone antagonist 
should be added
The next step should be addition of an alpha-blocker (doxazosin) or a beta-blocker (vasodilatatory agents are preferred)
The next step should be substitution of a loop diuretic for thiazide/thiazide-like diuretic, particularly in patients with severe kidney dysfunction
As the next step, addition of a direct arteriolar vasodilator (hydralazine) or a central acting agent (clonidine) should be considered
In exceptional cases of truly resistant hypertension, after all the above drug treatment measures have been tried, invasive treatment (renal denerva-
tion) may be considered
Patient selection for renal denervation should be a domain of hypertension specialists, and these procedures should be performed by invasive  
cardiologists in specialized centres
RAAS — renin-angiotensin-aldosterone system
Using this definition, resistant hypertension is 
a common clinical problem. In Poland, the propor-
tion of patients with resistant hypertension has been 
estimated at 10–13% of all treated hypertensives. 
Patients with resistant hypertension are characterized 
by an increased cardiovascular risk compared to those 
with good on-treatment BP control. Cardiovascular 
risk is also related to the number of antihypertensive 
drugs used.
Most commonly, pseudoresistance to treatment is 
observed due to the following reasons:
•	 non-compliance;
•	 inappropriate drug treatment — too low drug 
doses, drug combinations including no diuretic;
•	 BP increase in office measurements (white coat 
effect);
•	 errors during BP measurement;
•	 pseudohypertension.
The most common identifiable and correctable 
reasons for treatment resistance include:
1. Lack of appropriate lifestyle modifications, inc-
luding body weight increase and consumption of 
large amounts of alcohol.
2. Taking medications and substances that raise BP 
(e.g., non-steroidal anti-inflammatory drugs, glu-
cocorticosteroids, cocaine, licorice etc.).
3. Undiagnosed secondary hypertension. Common 
causes include obstructive sleep apnoea, renal 
disease, primary hyperaldosteronism, and renal 
artery stenosis.
4. Volume overload due to inappropriate diuretic 
treatment, progressive renal dysfunction, and lar-
ge sodium intake.
5. Advanced, irreversible vascular damage leading to 
a significant increase in the arteriolar wall-to-lu-
men ratio or reduced large artery compliance.
After excluding these often difficult-to-eliminate 
causes, the prevalence of true resistant hypertension 
is much lower. In patients with true resistant hyper-
tension, SBP values are usually very high, and the 
prevalence of severe left ventricular hypertrophy and 
renal dysfunction is increased.
5.12.1. Drug therapy of resistant hypertension
The algorithm for the management of resistant 
hypertension is shown in Table XXIII and Figure 7.
The recommended and effective three-drug com-
bination includes a RAAS inhibitor, thiazide/thiazi-
de-like diuretic, and a calcium antagonist. In some 
patients with resistant hypertension, changing pre-
vious medications to this three-drug combination, 
also using fixed-dose combined preparations, may 
be associated with an improvement of BP control. 
In resistant hypertension, a good response has been 
seen to a mineralocorticoid receptor antagonist as the 
next treatment step, particularly spironolactone, even 
in low doses (25–50 mg/day). An alpha-blocker (do-
xazosin) or beta-blocker may also be considered. In 
regard to the choice of a beta-blocker, benefits of va-
sodilating beta-blockers (carvedilol, nebivolol) have 
been highlighted. As the next step, it may be worth 
using a loop diuretic, particularly torasemide, instead 
of a thiazide/thiazide-like diuretic, in particular in 
patients with renal dysfunction, and obligatorily in 
patients with eGFR < 30 mL/min/1.73 m2. Of note, 
some older generation antihypertensive drugs may be 
effective in the treatment of resistant hypertension, i.e. 
direct arterial vasodilators (hydralazine) and central 
sympatholytic drugs (clonidine, rilmenidine).
In resistant hypertension, twice daily dosing of 
antihypertensive drugs is frequently necessary.
5.12.2. Renal denervation
Renal denervation is based on a solid theoretical 
background to expect effectiveness of this approach 
in the treatment of hypertension. Initial results of 
the Symplicity-HTN1 and HTN2 studies indicated 
that this procedure is highly effective. In addition, 
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Figure 7. Management algorithm in resistant hypertension
a beneficial effect on the glycaemic profile and im-
provement of the apnoea-hypopnea index (AHI) in 
patients with obstructive sleep apnoea was seen. 
The interest in renal denervation and its importance 
as the last-resort therapy of resistant hypertension 
decreased significantly with the publication of the 
results of the randomized Symplicity-HTN3 study, 
showing no significant BP-lowering effect at 6 mon-
ths of follow-up. Although further analyses showed 
higher efficacy of renal denervation in Caucasians, 
patients below 65 years of age, those without renal 
failure and treated with an aldosterone antagonist, 
even in these patient groups the overall BP re-
duction was modest, below 10 mm Hg. However, 
the procedure was shown to be safe. In contrast, 
the randomized PRAGUE-15 study showed that 
renal denervation is equally effective at lowering 
BP as adding spironolactone, and the randomized 
DENERHTN study showed that in patients with 
resistant hypertension despite use of a RAAS inhi-
bitor, a calcium antagonist and a diuretic, denerva-
tion was associated with more effective BP lowering 
than adding further antihypertensive medications, 
including spironolactone.
According to the current expert opinion on re-
nal denervation in the treatment of hypertension 
in Poland, published before the results of Symplici-
ty-HTN3, PRAGUE-15 and DENERHTN studies 
were reported, this procedure is indicated for offi-
ce SBP ≥ 160 mm Hg (mean of 3 measurements) 
during treatment with at least 3 antihypertensive me-
dications in full doses, including a diuretic. Seconda-
ry hypertension, and in particular primary hyperal-
dosteronism, should be excluded in these patients. 
Following release of the Symplicity-HTN3 study, 
it seems reasonable to add spironolactone to drug 
treatment in patients who are considered candidates 
for renal denervation.
Currently, pending confirmation of the long-term 
effectiveness of renal denervation, it is recommended 
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that patient selection for this procedure should be 
limited to specialized hypertension units, and the-
se procedures should be performed by experienced 
invasive cardiologists.
5.13. Life-threatening conditions
Conditions that require a rapid intervention due 
to high BP values (≥ 180 and/or 120 mm Hg) may 
be categorized into hypertensive emergencies and 
urgencies.
5.13.1. Hypertensive emergencies
In hypertensive emergencies, severe BP eleva-
tion is associated with acute complications that 
are immediately life-threatening (encephalopa-
thy, myocardial infarction, acute coronary syn-
drome, pulmonary oedema, stroke, head trauma, 
eclampsia, massive bleeding, aortic dissection). In 
these circumstances, admission to an intensive care 
unit is required and parenteral antihypertensive 
therapy is often necessary. The management of 
hypertensive emergencies depends on the type of 
target organ damage, ranging from no interven-
tion or only very cautious BP reduction in acute 
stroke to immediate BP reduction in acute pulmo-
nary oedema or aortic dissection. In most cases, 
immediate BP reduction is suggested, with the 
target of BP lowering by 25% within first hours of 
treatment using available parenteral antihyperten-
sive medications (Table XXIV).
Table XXIV. Intravenous antihypertensive medications 
available in Poland
Urapidil
Ebrantil 25 — 5 mg/mL (25 mg/5 mL) — 5 mL ampoules
Dosing: bolus 12.5–25 mg IV, followed by IV infusion 5–40 mg/min
Nitroglycerin
Perlinganit — solution for IV infusion 1 mg/mL (10 mg/10 mL)  
— 10 mL ampoules
Nitracor — solution for IV infusion 2 mg/mL (10 mg/5 mL)  
— 5 mL ampoules
Dosing: 5 mg IV, followed by IV infusion 4 mg/h
Esmolol
Esmocard — 100 mg/10 mL — 10 mg/mL (100 mg/10 mL)  
— 10 mL ampoules
Esmocard — 2500 mg/10 mL — 250 mg/mL (2.5 g/10 mL)  
— 10 mL ampoules
Dosing: 0.5–1 mg/kg IV, followed by 50–300 mg/kg/min IV
Furosemide
Furosemide Kabi, Furosemidum Polfarmex, Furosemidum Polpharma 
— 10 mg/mL (20 mg/2 mL) — 2 ml ampoules
Dosing: 20–40 mg IV initially, followed by 20 mg IV every 2 hours as 
needed; larger doses should be given as IV infusion
IV — intravenous. In emergencies, labetalol, nicardipine, and sodium nitroprusside may also 
be given IV but these drugs are currently not available in Poland
5.13.2. Hypertensive urgencies
In hypertensive urgencies, largely elevated BP is 
not associated with an immediately life-threatening 
condition. Most patients do not require hospital ad-
mission, but immediate combined oral antihyperten-
sive therapy is needed, and less frequently parenteral 
therapy should be initiated. Hypertensive urgencies 
include conditions associated with hypertensive drug 
withdrawal or dose reduction, epistaxis, acute glo-
merulonephritis with high BP values, drug-induced 
hypertension, and hypertension associated with spi-
nal cord trauma.
6. Treatment of concomitant risk factors 
(non-BP-lowering therapy)
6.1. Lipid-lowering drugs
Hypercholesterolemia is more prevalent in hyper-
tensive patients compared to the general population, 
as is atherogenic dyslipidaemia in patients with con-
comitant diabetes. Multiple clinical trials on the use 
of statins in primary and secondary prevention, in 
which hypertensive patients constituted a significant 
proportion of the study populations, indicate that an 
optimal reduction of the global cardiovascular risk 
may be obtained by simultaneous reduction of BP 
and LDL cholesterol level. In patients with hyper-
tension and cardiovascular disease, statin treatment is 
mandatory based on the general guidelines of cardiac 
societies that recommend serum LDL cholesterol le-
vel lowering below 70 mg/dL. Based on the results of 
recent randomized clinical trials, systematic reviews, 
and metaanalyses, optional LDL cholesterol level 
lowering below 55 mg/dL has been even suggested in 
patients at the highest cardiovascular risk.
Initiation of statin treatment is also recommen-
ded in all high and very high risk patients (10-year 
risk of a cardiovascular event > 20%) without overt 
cardiovascular disease regardless of the degree of 
BP elevation (atorvastatin in the ASCOT study), 
aiming for target serum LDL cholesterol level below 
100 mg/dL, and according to some societies below 
70 mg/dL. In the ASCOT study, it was also shown 
that adding a statin to amlodipine- and perindo-
pril-based antihypertensive treatment reduced the 
cardiovascular event rate more than adding a statin to 
atenolol- and thiazide diuretic-based treatment. Sta-
tin should also be used in hypertensive patients with 
moderate cardiovascular risk (> 15–20%; rosuvasta-
tin in the JUPITER study), even in case of moderate 
hypercholesterolemia, aiming for target serum LDL 
cholesterol level below 115 mg/dL (Figure 8).
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Clinical profile Blood pressure [mm Hg]
High normal  
(130–139/85–89)
Grade 1 hypertension 
(140–159/90–99)
Grade 2 hypertension 
(160–179/100–109)
Grade 3 hypertension  
(≥ 180/110)
No risk factors
1–2 risk factors Statin
LDL < 115 mg/dL
Statin
LDL < 115 mg/dL
Statin
LDL < 100 mg/dL
≥ 3 risk factors Statin
LDL < 115 mg/dL
Statin
LDL < 100 mg/dL
Statin
LDL < 100 mg/dL
Target organ damage,  
diabetes, CKD stage 3
Statin
LDL < 100 mg/dL
Statin
LDL < 100 mg/dL
Statin
LDL < 100 mg/dL
Statin
LDL < 100 mg/dL
Overt cardiovascular disease, 
CKD stage ≥ 4
Statin
LDL < 70 mg/dL
Statin
LDL < 70 mg/dL
Statin
LDL < 70 mg/dL
Statin
LDL < 70 mg/dL
Figure 8. Indications for statin therapy in hypertensive patients in relation to the global cardiovascular risk
CKD — chronic kidney disease (stage 3: eGFR 30–59 mL/min/1.73 m2; stage ≥ 4: eGFR < 30 mL/min/1.73 m2)
Clinical profile Blood pressure [mm Hg]
High normal  
(130–139/85–89)
Grade 1 hypertension 
(140–159/90–99)
Grade 2 hypertension 
(160–179/100–109)
Grade 3 hypertension  
(≥ 180/110)
No risk factors ASA
(after BP is normalized!)
1–2 risk factors ASA
(after BP is normalized!)
≥ 3 risk factors ASA
(after BP is normalized!)
ASA
(after BP is normalized!)
Target organ damage,  
diabetes, CKD stage 3 ASA
ASA
(after BP is normalized!)
ASA
(after BP is normalized!)
ASA
(after BP is normalized!)!
Overt cardiovascular disease, 
CKD stage ≥ 4 ASA ASA ASA ASA
Rycina 9. Wskazania do stosowania kwasu acetylosalicylowego u pacjenta z nadciśnieniem tętniczym w zależności od globalnego ryzyka 
sercowo-naczyniowego
ASA — acetylsalicylic acid; CKD — chronic kidney disease (stage 3: eGFR 30–59 mL/min/1.73 m2; stage ≥ 4: eGFR < 30 mL/min/1.73 m2)
6.2. Antiplatelet therapy
In patients with hypertension and cardiovascular 
disease, use of acetylsalicylic acid (ASA) is mandatory 
based on the general guidelines of cardiac societies 
that recommend a 75 mg dose. In these cases, ASA 
treatment should be used regardless of the degree of 
BP control. A useful fixed-dose combination product 
in these patients is a combination of beta-blocker 
and ASA (bisoprolol + ASA).
A recently published large metaanalysis that eva-
luated the rates of major bleeding events in patients 
receiving long-term ASA treatment has changed the 
approach to the use of this drug in primary preven-
tion. It has been shown that the net benefits of ASA, 
measured as the difference between the cardiovascu-
lar event rate reduction and the increase in the major 
bleeding event rate, have not been clearly established 
in this patient population. Thus, use of ASA for this 
indication requires evaluation of the risk-to-bene-
fit ratio. Based on these recent reports, a low ASA 
dose should be considered only in hypertensive pa-
tients with a high (20–30%) or very high (> 30%) 
global cardiovascular risk. To minimize the risk of 
haemorrhagic stroke, it is recommended to initiate 
ASA treatment in these patients only after elevated 
BP has been fully controlled (Figure 9). In view of 
these increasing limitations regarding the use of ASA 
in primary prevention, alternative substances with 
antiaggregant properties that have been evaluated in 
clinical trials (e.g., standardized tomato extract which 
exerts a weaker antiplatelet effect compared to ASA 
but has a more pleiotropic activity range) may be 
considered in patients with uncomplicated hyperten-
sion and moderate to high cardiovascular risk.
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7. Methods to improve blood pressure 
control in hypertensive patients
Published studies indicate that many hyperten-
sives are unaware of their elevated BP values, and 
even if they are aware of their hypertension, many 
individuals remain untreated. In addition, target BP 
levels are infrequently reached regardless of whether 
the treatment is undertaken by specialists or general 
practitioners, and the proportion of patients aware of 
their hypertension and the need to control elevated 
BP is relatively low, particularly among individuals 
without overt cardiovascular disease.
In clinical practice, two major causes of poor BP 
control may be identified:
•	 poor patient compliance;
•	 therapeutic inertia.
Uncompliant patients may be divided into those 
who permanently discontinue the therapy and those 
who use their medications in an inappropriate way 
(e.g, irregular drug intake, including delayed dosing 
and multiple short-lasting treatment interruptions).
Therapeutic inertia (i.e., failure to undertake ap-
propriate therapeutic measures despite a lack of 
adequate BP control in the patient) stems from 
several reasons, including the uncertainty regar-
ding the risk associated with elevated BP values, 
particularly in the elderly, concerns about excessive 
reduction of vital organ perfusion by BP lowering 
(J curve phenomenon), and the possibility of adver-
se drug effects.
Poor patient compliance is particularly frequent 
regarding lifestyle changes but also affects the use of 
prescribed medications. Studies indicate that more 
than one third of patients discontinue antihyper-
tensive drug therapy by 6 months, and about half 
of patients discontinue it by one year. In addition, 
about 10% of patient forget to take their medication 
on any given day. It is currently believed that provi-
ding patients with easily comprehensible educational 
materials distributed by media or available in phy-
sician offices and pharmacies has a beneficial effect 
of patient knowledge and motivation. Compliance 
may be significantly improved by simplifying the 
treatment scheme (use of fixed-dose combinations 
is preferred) and engaging patients in home BP me-
asurements. Ineffective treatment of hypertension 
is often related to the lack of adequate patient-phy-
sician cooperation. Educational efforts beyond the 
traditional model of treating hypertensive patients 
may lead to improved patient-physician cooperation 
and increased treatment effectiveness.
